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 Earlier studies indicate that Gi mediates enhanced renovascular responses to Ang II in 
SHR.  The potentiation of Ang II by the Gi pathway is blocked by pretreatment with pertussis 
toxin, an inhibitor of Gi.  The Gi pathway is also activated by receptors for PP-fold peptides; 
NPY, PYY, and PYY3-36.  Therefore, we hypothesize that in genetically predisposed models 
of hypertension PP-fold peptides augment renovascular responses to endogenous Ang II. 
 
 Our study shows that LPNPY, an analogue of NPY selective for the Y1 receptor,  
potentiates Ang II responses in SHR, but not WKY, kidneys in vitro. LPNPY’s ability to 
potentiate Ang II renovascular responses is dependent on the Y1 receptor and an intact Gi 
pathway.  The renal expression of Y1 receptors is similar in SHR versus WKY. 
 
 Our study also demonstrates that PYY3-36, selective for the Y2 receptor, potentiates 
renovascular responses to Ang II in SHR, but not WKY, in vitro.  PYY3-36 is dependent on an 
intact Y2-Gi pathway, and the Y2 receptor is similarly expressed in the kidney of both strains. 
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  In comparing the PP-fold peptides, PYY is the most efficacious at potentiating Ang II-
induced renovascular responses.  Lower levels of these peptides have little effect on renal 
vasculature.  Yet, these peptides are released with other Gi coupled agonists, namely NE that acts 
on ∀2-adrenoceptors.  We observe a significant enhancement of Ang II-induced renal 
vasoconstriction with low level combinations of UK 14,304, an ∀2-adrenoceptor agonist, and 
PYY/NPY.   
 
We demonstrate, in SHR, that nerve stimulation potentiates renal vasoconstrictive 
responses to Ang II.   This interaction is dependent on an intact Y1-Gi pathway suggesting that 
NPY plays a predominate role in increasing renal vascular responses. 
 
PYY is a more potent agonist at augmenting renal vascular responses than is PYY3-36.  
Blockade of the conversion of PYY to PYY3-36 via a DPPIV inhibitor, P32/98, results in an 
increase in MABP in SHR.  We also demonstrate that this effect is dependent on the Y1 receptor 
pathway.  This project demonstrates that PP-fold peptides may play a role in the etiology of 
genetic hypertension. This project is significant because it suggests a link between a high 
fat diet, sympathetic activation, and hypertension in a genetically susceptible animal. 
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CHAPTER 1 
Introduction 
 
1.1 Hypertension 
Hypertension is a major, worldwide problem.  The American Heart Association has 
published recent estimates that in the United States 1 in 3 adults has high blood pressure, yet 
most hypertensive adults are unaware of their high blood pressure.[1]  This disease, labeled as a 
“silent killer”, leads to serious complications; including stroke, heart failure, renal disease, and 
ultimately death.  There are two subsets of hypertensive patients; essential hypertensives and 
secondary hypertensives.  While physicians are capable of pinpointing the origin of high blood 
pressure in individuals that have secondary hypertension, the pathophysiology of essential 
hypertension remains unclear and is due to a combination of environmental and genetic factors.  
Although lifestyle modifications in hypertensive patients, such as weight loss, sodium intake 
reduction, physical activity, and lowering of alcohol consumption, lower blood pressure and 
have become vital parts in the management of hypertension, patient compliance is 
problematic.[2]  Therefore, a major effort is underway to establish the fundamental causes of 
hypertension and to develop permanent treatments. 
Researchers in the field of hypertension have suggested the theories of an overactive 
renin-angiotensin system (RAS) and/or an overactive sympathetic nervous system (SNS) as the 
leading instigators in the development of essential hypertension.[2] To date, the most effective 
pharmacological treatment of the disease has been through the disruption of the RAS because of 
its primary role in regulating blood pressure.  Normally, junxtaglomelur cells within the kidney 
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release renin when signals of low blood pressure, low salt content or beta adrenergic activation 
occur.  Renin in turn catalyzes the conversion of angiotensinogen to angiotensin I, and then 
angiotensin I is rapidly converted to angiotensin II (Ang II) by angiotensin converting enzyme 
(ACE) released from endothelial cells within the kidney.  Ang II is the active protein in the RAS, 
and is responsible for raising arterial blood pressure through primarily the angiotensin type I 
receptor (AT1R) by increasing total peripheral resistance and inhibiting excretion of sodium and 
water by the kidneys.[3]  
Elucidation of RAS has resulted in the development of several classes of drugs that 
regulate blood pressure in individuals with hypertension:  ACE inhibitors block the conversion 
of Ang I to Ang II;  Angiotensin receptor blockers interfere with Ang II communication with its 
receptor; Beta-blockers inhibit beta-adrenergic activation of renin release; Calcium channel 
blockers and diuretics increase the excretion of sodium by the kidneys, thus counteracting some 
of the effects of Ang II.   While these drugs have been proven to lower blood pressure, many 
hypertensives have to take a combination of these drugs to achieve a healthy blood pressure. 
The Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure has released an algorithm for the treatment of 
hypertension, figure 1.1.  While this figure demonstrates an effective method in treating high 
blood pressure, many individuals go untreated.  In most cases, lifestyle modifications prove to be 
too difficult for most patients to comply, and the physician then prescribes pharmacological 
control.  However, some patients lack the ability to comply with taking their medication as 
prescribed, and/or patients with fixed incomes do not have the means to finance the medications 
needed to effectively treat their high blood pressure.  Therefore, only a minority of hypertensives 
are adequately treated.  Clearly, a better  
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FIGURE 1.1 
An algorithm for treatment of hypertension published in the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure by the National Institutes of Health.[2] 
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understanding of the development and maintenance of the disease is needed in order to better 
treat this wide-spread and devastating disease. 
 
1.1.A   The Spontaneously Hypertensive Rat  
To experimentally approach the pathophysiology of hypertension, researchers have 
created a number of animal models of high blood pressure.  The spontaneously hypertensive rat 
(SHR), a genetic model of hypertension, is one such animal model.  These rats were developed 
by selective inbreeding of Wistar Kyoto Rats (WKY) with increased blood pressure by 
researchers at the Kyoto School of Medicine, Okamoto, Japan in the 1950s.[4,5]  In many 
respects, SHR resemble high blood pressure in the human population (for example, spontaneous 
elevation of blood pressure with age, sensitivity to antihypertensive drugs effective in humans, 
and involvement of the RAS and sympathetic nervous system in the development and 
maintenance of hypertension).  Consequently, the SHR is the most studied hypertensive model 
with close to 13,000 papers to date being published on research with SHR.  Even though 
research on these animals has revealed a vast amount of information, the precise cause of 
hypertension in these animals is still unknown.  
Importantly, the development of hypertension in SHR is dependent on an intact 
RAS.[4,5]  In this regard, treatment of SHR with captopril, an ACE inhibitor, lowers blood 
pressure to similar levels as its WKY normotensive counterpart.  The normalization of blood 
pressure by blockade of RAS is prolonged even following the removal of drugs that inhibit the 
RAS pathway suggesting the possibility of an acute preventive pharmacological method.[5]  
Moreover, transplantation studies reveal that, in addition to the RAS, the SHR kidney is pivotal 
to the pathophysiology of hypertension in the SHR.[6,7]  When normotensive WKY animals are 
transplanted with an SHR kidney they become hypertensive while the reverse is also true.  The 
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renal sympathetic nervous system also appears to importantly contribute to the pathophysiology 
of hypertension in SHR.  In support of this latter concept, chronic denervation of the SHR kidney 
both delays the development of hypertension and attenuates the maximum increase in blood 
pressure in SHR[8-11].  Thus there appears to be a co-involvement of the RAS, the sympathetic 
nervous system and the kidney in SHR hypertension.   
Many studies have been performed in search of a possible explanation for the co-
involvement of the RAS and the kidney in SHR hypertension.  In this regard, studies do not 
support an increased expression of renal Ang II receptors or increased levels of circulating or 
renal Ang II; also, SHR do not have altered renal Ang II degradation rates.[12-15]  However, 
SHR do exhibit increased renovascular responses to Ang II as shown in figure 1.2[16,17], and 
this appears to be the explanation for the co-involvement of the RAS and the kidney in SHR 
hypertension. 
 
1.1.B Pathophysiology Of Hypertension In The SHR 
 Previous research in the Jackson laboratory indicates that the inhibitory G protein (Gi) 
mediates in part the enhanced renovascular response to Ang II in SHR.  In this regard, pertussis 
toxin (PT), an inhibitor of Gi, abolishes the increased renovascular response to Ang II in SHR as 
shown in figure 1.3.[18,19]   Additionally, figure 1.4a/b, reveals that activation of the α2-
adrenoreceptor via an α2-adrenoreceptor agonist, UK14,304, which is Gi-coupled, results in 
potentation of renovascular responses to Ang II in SHR (b) but not WKY (a).  However, 
pretreatment of SHR with PT blocks the potentiation of Ang II-induced renovasconstriction due 
to UK14,304.[12,20]  Yet, there are many Gi-coupled receptors, and these previous results 
suggest the possibility of other agonists causing a potentiation of Ang II-induced renovascular 
tone in a genetic susceptible model.   
 
5
 1.1.C Hypothesis  
 Y1 and Y2 receptors, PP-fold peptide receptors, are expressed in the kidney and known to 
activate the Gi-pathway.[21,22,23]  Thus, we hypothesize that these Gi coupled receptors also 
have the ability to potentiate Ang II-induced renal responses in the appropriate genetic milieu.  
In way of background, Section B will review the PP-fold peptides and their receptors. 
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FIGURE 1.2 
 Absolute change in renal vascular resistance following infusion of Ang II of increasing 
concentrations (0.1, 0.3, 1, 3, 10 nmoles/min) in WKY (circle) and in SHR (triangle). [16]
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FIGURE 1.3 
 Absolute change in renal vascular resistance following infusion of Ang II of increasing 
concentrations (0.1, 0.3, 1, 3, 10 nmoles/min) in pertussis toxin pretreated  WKY (circle) and 
SHR (triangle).[18] 
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FIGURE 1.4 
 Changes in perfusion pressure induced by angiotensin II (10 nM) in control WKY 
kidneys (panel A), UK-14,304 (10 nM)-treated WKY kidneys (panel A), control SHR kidneys 
(panel B), UK-14,304-treated SHR kidneys (panel B), and UK-14,304-treated kidneys removed 
from SHRs pretreated 3 to 4 days earlier with 30 µg/kg pertussis toxin (panel B). Values 
represent means ± S.E.M. from six animals.[20] 
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1.2 PP-Fold Peptides And Their Receptors 
 The PP-fold peptide family is made up of neuropeptide Y (NPY), peptide YY (PYY), and 
pancreatic polypeptide (PP).  These peptides are all 36 amino acids long with an amidated 
carboxy-terminus, and share a common hairpin-like three dimensional structure, labeled the PP-
fold.  While each peptide has a different origin, these peptides are all found in the bloodstream 
and act via multiple G-protein coupled receptors (GPCR).  By use of x-ray crystallography and 
nuclear magnetic resonance, the general structure of these peptides has been elucidated. Figure 
1.5 is a structural representation of PYY, which has a similar profile to NPY. [24]  Amino acid 
residues 1-8 form a type II proline helix followed by a loop.  Residues 15-32 form an α-helix, 
and the four most carboxy-terminal residues are in a flexible loop conformation.[25]  The PP-
fold peptides are known agonists for the Y receptor family that is Gi coupled. 
 
1.2.A NPY Review 
 NPY was isolated within the porcine brain in the early 1980s by a method that captures 
peptides with an amidated-carboxy terminus. [26]  Generated from a 97 amino acid precursor, 
NPY is widely distributed throughout the brain and the periphery.[25,26]   NPY is synthesized in 
the nerve cell body and co-stored with noradrenaline in large dense-cored vesicles.  The vesicles 
are then transported via axonal transport to sympathetic nerve terminals, where the molar ratio of 
noradrenaline:NPY has been estimated to be about 150:1.[27]  NPY is subsequently co-released 
with sympathetic activation and an influx of calcium into the sympathetic nerve terminal.  This 
effect is increased following α-adrenoceptor blockade, β-adrenoreceptor stimulation, or Ang II 
receptor activation.[28-30]  The release of NPY is also affected by other hormones involved in 
energy homeostasis.  Ghrelin increases NPY mRNA while leptin inhibits NPY release.[25]   
 
10
  
 
 
 
 
FIGURE 1.5 
 Structure of PYY in solution. Left: ensemble of 20 lowest energy structures  
superimposed over backbone atoms of residues 17–31 and 5–7. Right: secondary structure of 
PYY of a representative conformer.[24] 
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 NPY, conserved among most species, is a potent orexigenic peptide leading to an 
increase in food intake and a decrease in energy expenditure.  Within the vasculature system, 
NPY has been demonstrated as vasoconstrictor as well as stimulator of smooth muscle 
proliferation.[31]  However, centrally administered NPY has alternating effects that include a 
decrease in food intake and an increase in energy expenditure.  Central NPY also reduces arterial 
blood pressure.[25-31]  NPY levels vary in several diseases that may be linked to hypertension.  
In this respect, several cardiovascular dysfunctions and tumors have been associated with 
increased NPY plasma levels, and NPY levels are altered in conditions that involve energy 
balance, such as diabetes.[25] 
 
1.2.B NPY Receptor (Y Receptor) Review 
 In the late 1980s, NPY postjunctional and prejunctional receptors were postulated, and 
named Y1 and Y2 receptors, respectively (Y1R/Y2R).[32,33]  Since that time, the Y receptor 
family has grown to at least four subtypes of GPCRs belonging to the rhodopsin-like superfamily 
of receptors (Y1, Y2, Y4, Y5).  NPY binds with high affinity to Y1, Y2 and Y5 receptors, but not 
Y4 receptors [25], whereas Y3 receptors most likely do not exist[33].  Y5 receptors are expressed 
predominantly in the central nervous system, not the kidney, and it has been suggested that 
mainly Y1 and Y2 are responsible for vascular control.[31,34,35]  The Y1 receptor is located 
mostly postjunctionally, and is thought to mediate its vasoconstrictive activity by coupling 
through the cyclic adenosine monophosphate (cAMP)/phospholipase C pathway.  On the other 
hand, the Y2 is located mostly prejunctionally and has the ability to act as a negative feedback 
inhibitor decreasing the release of NPY. Although this information seems to suggest an opposing 
effect with the activation of these receptors, these receptors vary in their action and location.  
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The Y2 receptor can cause vasoconstriction, and Y1 receptors have been found 
presynaptically.[31]  Therefore, because Y1 and Y2 receptors coupled to Gi[33], exist in the 
kidney and are stimulated by NPY, it is conceivable that the co-involvement of the RAS, 
sympathetic nervous system and kidney in SHR hypertension is mediated in part by activation of 
Y1 and/or Y2 receptors leading to a potentiation of Ang II-induced renal vasoconstriction in the 
SHR kidney. 
 
1.2.C PYY Review 
 Similarly to NPY, PYY was first isolated using a method that captures peptides with an 
amidated carboxy terminus, but this regulatory peptide was found in the porcine intestine.[26]  
PYY has tyrosines at both ends of its 36 amino acid sequence and thus its name was derived 
from this finding.   PYY is synthesized and released from endocrine L-cells of the terminal small 
bowel, caecum, colon, and rectum.[25, 36-48]  Researchers have demonstrated that PYY is 
released from the gastrointestinal tract (GI) in response to meals, and that plasma levels increase 
approximately 4-fold after 30 minutes of a meal as shown in figure 1.6.[49]  While the removal 
of the ileum and colon result in the loss of PYY release, researchers have observed that direct 
exposure of PYY-releasing cells to fat leads to the release of the peptide.[45,47]  It has been 
observed that PYY levels begin to increase as early as 15 minutes following a high-fat meal and 
that these levels remain elevated for more than 6 hours.  Researchers have suggested that the 
release of PYY is therefore regulated by more than direct exposure of fat, but also by some 
neuronal pathway.  The finding of PYY within neurons further corroborates this 
idea.[43,44,47,49] 
 PYY is abundant in human blood, and passes through the blood brain barrier via  
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FIGURE 1.6 
 Peptide YY (PYY) release by an intraduodenal meal (3 ml of a semi-liquid diet containing 
21 kJ provided as 57% carbohydrate, 13% lipid and 30% protein) in normal rats (Meal, n = 18 
rats) and in caecocolonectomized rats (+CX, n = 9). In a third group of 5 rats, saline was  
administered instead of the meal as a control (Saline). A Time course of plasma PYY. B The 120 
min integrated PYY responses over the basal level. Mean ± SEM; *** P<0.001 versus Meal [49]
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transmembrane diffusion.[48]   In this respect, PYY has demonstrated similar activity as other 
peptides, such as leptin, ghrelin, and NPY, involved in gut-brain communication.  Thusly, PYY 
can affect appetite and influence neuronal activity at the arcuate nucleus.[34]  Within the GI, 
PYY has demonstrated the ability to inhibit gall bladder secretion, gut motility, and pancreatic 
secretion.  PYY has also been shown to inhibit fluid and electrolyte secretion in the intestinal 
tract functioning as an “ileal brake.”[25,42,49]  PYY has also been observed as a 
vasoconstrictive agent. 
 Like NPY, PYY acts via the Y receptor family.  In this respect, PYY has demonstrated 
similar affinity to Y1 and Y2 receptors as NPY.  Table 1.1 compares the affinities of agonists for 
the receptors.[25]   
 
1.2.D  PYY3-36 Review 
 PYY containing endocytes also release a truncated form of PYY, where amino acids 1 
and 2 have been removed.  Although both PYY peptides are released from the gastrointestinal 
tract postprandially in direct proportion to meal size, the truncated PYY levels increase more in 
response to food.[42-46]  PYY3-36 has high affinity for the Y2 receptor, but has no affinity for the 
Y1 receptor.  This change in affinity would suggest that PYY3-36 has opposing effects compared 
to its full length counterpart.  Indeed, researchers have observed that PYY3-36 is an inhibitor of 
food intake.  It is believed that PYY3-36 elicits this function by blockade of NPY release through 
the negative feedback of the Y2 receptor.[42,46]  The blockade of NPY by PYY3-36 results in 
activation of adjacent pro-opiomelanocortin neurons which are similar in action to leptin.[39]  
These effects have suggested PYY3-36 as a potential candidate in both weight and glucose 
control.[50] 
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Table 1.1 
 Cloned Y receptors and affinity profiles for each form.[25] 
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1.2.E  DPPIV Review 
 Although both PYY constructs are released from L-cells within the GI, it is thought that 
PYY is the proform, whereas PYY3-36 has been labeled the active form.  The conversion of PYY 
to PYY3-36 is created via an aminopeptidase, dipeptyl dipeptidase IV (DPPIV).[51-56]  DPPIV 
has gained a lot of attention lately because of its proposed role in glucose homeostasis.  The 110-
150 kDa protein is ubiquitously expressed as a homodimeric membrane-bound protein that can 
be shed into a soluble form.[55]  The highest concentrations have been found on the proximal 
tubules in the kidney and epithelial cells of the small intestines.  Although researchers have 
demonstrated many peptides cleaved by DPPIV, DPPIV inhibitors have taken the highlight of 
DPPIV research because of their ability to lower blood glucose.  Glucagon-like protein I (GLPI) 
stimulates insulin secretion and biosynthesis while inhibiting the release of glucagon.  GLPI is a 
substrate for DPPIV and is cleaved to a truncated non-active form.[51-54]  Therefore, inhibition 
of DPPIV would lead to increases in GLP and decreases in blood glucose that could prove 
beneficial in type 2 diabetes.  On the other hand, as mentioned previously DPPIV has 
demonstrated activating ability with PYY that would lead to a construct that would work 
primarily through the Y2 receptor.  Thus, DPPIV may be a factor in determining which Y 
receptor is activated. 
 
1.3  Detailed Hypothesis And Objectives 
 The focus of this project is the ability of PP-fold peptides to augment Ang II-induced 
renovascular responses in SHR and WKY kidneys.  The rationale for this focus is that 1) the Gi 
pathway appears to augment renovascular responses to Ang II in SHR, but not WKY, and 2) 
receptors for PP-fold peptides appear to activate the Gi pathway.  The significance of this project 
 
17
is that 1) NPY is released from renal sympathetic nerves in response to sympathetic activation, 
and 2) PYY and PYY3-36 are released from the intestines in response to a meal.  Therefore our 
HYPOTHESIS is that in genetically predisposed individuals (i.e. individuals with “SHR-like” 
kidneys),  PP-fold peptides acting on PP-fold receptors augment renovascular responses to 
endogenous Ang II and contribute to the etiology of hypertension.  
 In this respect, the following OBJECTIVES where undertaken: 
1) Determine whether Y1 receptor activation potentiates renal vasoconstriction in SHR 
or WKY kidneys (chapter 3) 
2) Determine whether Y2 receptor activation potentiates renal vasoconstriction in SHR 
or WKY kidneys (chapter 3) 
3) Compare the effects of the naturally occurring PP-fold peptides in their ability to 
augment renovascular responses to Ang II in SHR kidneys (chapter 4) 
4) Determine whether the activation of the α2-adrenoreceptor adds to any augmentation 
of Ang II induced renovascular responses by the PP-fold peptides in SHR (chapter 4) 
5) Determine whether endogenous PP-fold peptides released during renal nerve 
stimulation regulate renovascular responses to Ang II in SHR or WKY kidneys 
(chapter 5) 
6) Determine whether blockade of PYY conversion to PYY3-36 via DPPIV has an effect 
on arterial blood pressure in SHR or WKY (chapter 6) 
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 CHAPTER 2 
EXPERIMENTAL METHODS 
 
2.1 Drugs.  
   Ang II, NPY, PYY (sometimes referred to as PYY1-36), PYY3-36, [Leu31,Pro34]-
neuropeptide Y (LPNPY), aldosterone, hydrocortisone, captopril and UK14,304 were obtained 
from Sigma (St. Louis, MO). BIBP3226 and BIIE0246 were obtained from Tocris (Ellisville, 
MO). 
 
2.2 Animals. 
  Studies utilized adult (14-16 weeks-of-age) male SHR or WKY obtained from Taconic 
Farms (Germantown, NY).  The Institutional Animal Care and Use Committee approved all 
procedures.  The investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1996). 
 
2.3 Experiments In Isolated, Perfused Kidneys. 
  SHR and WKY were anesthetized with Inactin (90 mg/kg, i.p.), and the left kidney was 
isolated and perfused with Tyrode’s solution using a Hugo Sachs Elektronik-Harvard Apparatus 
GmbH (March-Hugstetten, Germany) kidney perfusion system as previously described[15].  
Briefly, all branches of the left renal artery and vein were ligated.  A PE-50 cannula was placed 
into the left renal artery, and a PE-90 cannula was placed into the left renal vein. The left kidney 
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was removed, attached to the perfusion system and allowed to stabilize for an hour before the 
experimental protocol.  Kidneys were perfused (single pass mode) at a constant flow (5 ml/min), 
and perfusion pressure was monitored with a pressure transducer. 
 
2.3.A  Protocol 1 
Ang II (Sigma) was infused at increasing doses to provide nominal concentrations in the 
perfusate of 0.3, 1, or 3 nmoles/L.  Each dose of Ang II was infused for two minutes, and the 
perfusion pressure was allowed to return to basal levels over the next five minutes before 
initiating the next higher dose of Ang II.  After the highest dose of Ang II, and following a rest 
period of 15 minutes, LPNPY (Sigma) was infused into the kidney to provide a concentration in 
the perfusate of 10 nmoles/L.  Ten minutes into the infusion of LPNPY, the kidney was 
restimulated with Ang II.  The response to Ang II was taken as the change in perfusion pressure 
during the Ang II infusion and was calculated as the perfusion pressure recorded at the end of the 
infusion of Ang II minus the basal perfusion pressure recorded just before the Ang II infusion.  
Time control experiments demonstrated that concentration-response curves to Ang II were stable 
over the duration of the experiment. 
 
2.3.B Protocol 2 
Ang II was infused to achieve a concentration in the perfusate of 0.3 nmoles/L.  After 10 
minutes, the infusion of Ang II was stopped, and the perfusion pressure was allowed to return to 
basal levels over the next 10 minutes, then LPNPY or PYY3-36 was infused into the kidney to 
provide a final concentration in the perfusate of 6 nmoles/L.  Twenty minutes into the infusion of 
LPNPY or PYY3-36, the kidney was restimulated with Ang II for 10 minutes.  Changes in 
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perfusion pressure in response to Ang II were calculated as described above.  Some of these 
experiments were conducted in kidneys obtained from SHR pretreated with pertussis toxin.  
Also, some of these experiments were conducted in kidneys in which BIBP3226 or BIIE0246 
was infused into the perfusate to provide a concentration in the perfusate of 1 µmole/L.  The 
infusions of BIBP3226 or BIIE0246 were initiated at the beginning of the one-hour rest period 
and continued until the end of the protocol.   
 
2.3.C Protocol 3 
 After the stabilization period, Ang II was infused to achieve a nominal concentration in 
the perfusate of 0.3 nmoles/L. After 10 minutes, the infusion of Ang II was stopped, and the 
perfusion pressure was allowed to return to basal levels over the next 10 minutes. Then the 
following agents were infused to achieve the indicated nominal concentration in the perfusate: 
NPY (0.1 nmoles/L), NPY (1 nmole/L), NPY (6 nmoles/L), PYY1-36 (0.1 nmoles/L), PYY1-36 (1 
nmole/L), PYY1-36 (6 nmoles/L), PYY3-36 (0.1 nmoles/L), PYY3-36 (1 nmoles/L), PYY3-36 (6 
nmoles/L), UK14,304 (10 nmoles/L), NPY (1 nmole/L) + UK14,304 (10 nmoles/L), PYY1-36 (1 
nmole/L) + UK14,304 (10 nmoles/L), PYY3-36 (1 nmole/L) + UK14,304 (10 nmoles/L), NPY (6 
nmoles/L) + BIBP3226 (1 µmole/L), PYY1-36 (6 nmoles/L) + BIBP3226 (1 µmole/L) or PYY3-36 
(6 nmoles/L) + BIIE0426 (1 µmole/L). In the case of those kidneys treated with BIBP3226 or 
BIIE0226, these antagonists were infused beginning from the outset of perfusion (i.e., during the 
stabilization period). Because a given kidney received only one treatment, this protocol 
represented 16 distinct groups with 6 to 7 kidneys per group (total of 98 kidney perfusion 
experiments). Twenty minutes into the treatments, the kidney was restimulated with Ang II for 
10 minutes. By using only a low concentration of Ang II and by limiting the experiment to two 
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challenges with Ang II, tachyphylaxis to Ang II was avoided and responses to Ang II were 
stable.  The response to Ang II was taken as the change in perfusion pressure during the Ang II 
infusion and was calculated as the perfusion pressure recorded at the end of the infusion of Ang 
II minus the basal perfusion pressure recorded just before the Ang II infusion. 
 
2.3.D Protocol 4 
 Experiments were conducted in 66 isolated, perfused rat kidneys using the protocol 
outlined in figure 2.1.  Immediately after initiating perfusion of the kidney, a platinum bipolar 
electrode was placed around the renal artery for renal nerve stimulation (RNS).  The electrode 
was connected to a Grass stimulator (model SD9E; Grass Instruments, Quincy, MA). After a 60 
minute rest period, prazosin (30 nmoles/L) was added to the perfusate to block α1-adrenoceptors 
so that RNS would not cause direct vasoconstriction and increase basal vascular tone.  This was 
necessary because changes in basal vascular tone might non-specifically elevate responses to 
Ang II.  Ten minutes after adding prazosin to the perfusate, RNS was simulated by going 
through the motions of activating the stimulator while not actually activating the stimulator 
(sham RNS).  Two minutes into the sham RNS, Ang II was infused into the renal artery for 
seven minutes to provide a final concentration of 100 pmoles/L, which is a physiological level of 
Ang II in SHR as recently determined by capillary electrophoresis[57].  This first response to 
Ang II was designated period 1.  At the end of the Ang II infusion, the kidney was allowed a rest 
period of 10 minutes, then the kidney was subjected to either sham RNS or RNS (biphasic, 5 Hz, 
1 millisecond pulse duration, 35 volts) for 9 minutes.  This frequency of RNS is well within the 
physiological range[21].  Two minutes into the sham RNS or RNS, Ang II was infused once 
again for seven minutes to provide a final concentration of 100 pmoles/L.  This second response  
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Control or Rauwolscine 10 nmoles/L or BIBP 1 µmole/L
Prazosin 30 nmoles/L
60’ RestStart
Perfusion
Ang II; 7’
Sham RNS: 9’10’
Ang II; 7’
Sham RNS or
RNS: 9’10’
Ang II; 7’
Sham RNS or
RNS: 9’10’
Period 1
Period 2 Period 3
 
 
FIGURE 2.1 
 Overview of the experimental protocol.  RNS, periarterial renal nerve stimulation; Ang 
II, angiotensin II. 
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to Ang II was designated period 2.  Next, the periarterial electrodes were repositioned, and after 
another 10-minute rest period, a third response to Ang II was obtained in the absence (sham 
RNS) or presence (RNS) of renal sympathetic activation (period 3).  Kidneys were randomly 
assigned to receive either sham RNS during periods 2 and 3 or active RNS during periods 2 and 
3. 
 In some experiments, either rauwolscine (10 nmoles/L, a highly selective α2-
adrenoceptor antagonist [58]) or BIBP3226 (1 µmole/L, a highly selective Y1 receptor antagonist 
[25]) was added to the perfusate at the beginning of kidney perfusion.  Also, some kidneys were 
removed from rats that had been pretreated three days earlier with an iv injection of pertussis 
toxin (30 µg/kg) to block Gi proteins as previously described by us [18].  Kidneys were randomly 
assigned to either no inhibitor, rauwolscine, or BIBP3226. 
 
2.4 Experiments In Kidney In Vivo. 
 
2.4.A  Protocol 1 
SHR (n=31) and WKY (n=31) were anesthetized with Inactin (90 mg/kg, i.p.), and 
animals were prepared as previously described [59]. Briefly, cannulas were inserted into the 
trachea, jugular vein and carotid artery. A digital blood pressure analyzer measured MABP via 
the carotid artery cannula. To remove the influence of endogenous catecholamines on α2-
adrenoceptors, both adrenal glands were removed and the left kidney was denervated. To replace 
loss of adrenal steroids, aldosterone and hydrocortisone were infused. A transit-time flow probe 
was positioned around the left renal artery to monitor renal blood flow (RBF). A 32-gauge 
needle connected to a catheter was placed into the renal artery, and animals were given a bolus 
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injection of captopril (30 mg/kg) to remove the influence of endogenous Ang II and a bolus of 
saline to improve hemodynamic stability. After one hour, SHR and WKY received an intrarenal 
infusion of either vehicle (control; n=7), UK14,304 (0.3 µg/kg per min; n=7), LPNPY (1 
µg/kg/min; n=7) or UK14,304 + LPNPY (n=10). Twenty minutes later while continuing the 
treatments, RBF and MABP were recorded just before and during the last minute of a five-
minute intrarenal infusion of Ang II (10 ng/kg per minute). Renovascular resistance (RVR) was 
calculated by dividing RBF per gram kidney weight into the MABP.  
 
2.4.B Protocol 2 
SHR (n=26) and WKY (n=12) were anesthetized with Inactin (90 mg/kg, i.p.), and 
animals were prepared as previously described [59]. Briefly, cannulas were inserted into the 
trachea, jugular vein and carotid artery. A digital blood pressure analyzer measured MABP via 
the carotid artery cannula.  After one hour, SHR and WKY received an intravenous infusion via 
the jungular vein of either vehicle, P32/98 (0.3, 1, 3 mg/kg), or P32/98 plus BIBP3226 (40 
µg/kg).   MABP were recorded just before and during the last minute of a ten-minute interval.  
 
 
2.5 RT-PCR For Y1 Or Y2 Receptor mRNA. 
Y1 or Y2 receptor mRNA was obtained from SHR and WKY preglomerular microvessels 
(PGMVs) and whole kidneys and measured as previously described for other receptors [15].  
Briefly, PGMVs were obtained by iron oxide injection into the renal artery followed by magnetic 
retrieval of PGMVs.  Total RNA was isolated from PGMVs or whole kidney with TRIzol 
reagent.  RNA was reverse transcribed and amplified using a Titanium One-Step RT-PCR Kit.  
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For the Y1 receptor, the forward primer was 5′-CTGATCGTGAACCTCTCCTTCT-3′ and the 
reverse primer was 5′-GTCGTGTAAGACAGCCTGTGAG-3′.  For the Y2 receptor, the forward 
primer was 5′-GGTCTGGCAGTACAAGTGTCC-3′ and the reverse primer was 5′-
GGTCGTTTTGTGCCTTCGCTG-3′.  Each PCR cycle consisted of denaturing at 94°C for 30 
seconds, annealing at 65°C for 30 seconds, and extension at 72°C for 60 seconds.  RT-PCR 
products were separated on a 1.2% agarose gel and gels were stained with ethidium bromide.  
 
2.6 Western Blotting For Y1 Or Y2 Receptor Protein. 
Y1 or Y2 receptor protein was obtained from PGMVs and whole kidneys and measured as 
previously described for other receptors [15].  Briefly, protein samples from whole kidneys and 
PGMVs were loaded onto a 7.5% acrylamide gel and subjected to SDS-PAGE using the Bio 
RAD mini-gel system.  Proteins were electroblotted onto PVDF membranes.  Membranes were 
blocked with 5% milk then incubated with primary antibody to either the Y1 or Y2 receptor 
(Sigma).  After washing, the membrane was incubated with horseradish peroxidase-conjugated 
donkey anti-rabbit IgG secondary antibody.  Membranes were then exposed to films, and the 
signals were detected by a Supersignal Substrate kit.  Band densities were quantitatively 
measured using Scion Image software. 
 
2.7 Statistical Analysis. 
Data were analyzed by paired or unpaired two-tailed Student’s t-test or one-factor or two-
factor analysis of variance, as appropriate.  The Fisher’s Least Significant Difference (LSD) test 
was used for post-hoc analyses if a significant analysis of variance was obtained.  The criterion 
of significance was P<0.05.  All data are presented as means ± SEM.  
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 CHAPTER 3 
PP-Fold Peptides And Ang II-Induced Renal Vasoconstriction 
 
3.1 Introduction  
 There appears to be a co-involvement of the RAS, the sympathetic nervous system, and 
the kidney in SHR hypertension.  Our previous research indicates that Gi mediates the enhanced 
renovascular response to Ang II in SHR as demonstrated in figure 1.2.  Activation of renal 
sympathetic nerves leads to the release of NPY, and consumption of a high fat diet results in the 
release of PYY1-36/PYY3-36.  NPY and PYY1-36/PYY3-36 bind Y receptors found within the renal 
vasculature.[25]  It is conceivable that the coinvolvement of the RAS, sympathetic nervous 
system, and the kidney in SHR hypertension is partially mediated by activation of Y receptors 
leading to a potentiation of Ang II-induced renal vasoconstriction in the SHR kidney. 
 The purpose of the present study was to test the hypothesis that Y1 and/or Y2 receptor 
activation potentiates renal vascular responses to Ang II selectively in SHR kidneys by a 
mechanism involving inhibitory G proteins.  In this regard, we examined the effects of LPNPY, 
a highly selective Y1 agonist, and PYY3-36, a highly selective Y2 agonist, on renovascular 
responses to Ang II in SHR and WKY kidneys in vitro in the absence and presence of a highly 
selective Y1 antagonist BIBP3226, a highly selective Y2 antagonist BIIE0246, or pertussis toxin 
to inhibit G proteins. 
 
3.2 Results 
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 Basal Renal Perfusion Pressures.  In this study, baseline renal perfusion pressures were 
similar (60 ± 3 and 52 ± 2 mm Hg) in WKY and SHR kidneys, respectively, and were not 
affected by any of the various treatments or combinations of treatments. 
 
Experiments in Isolated, Perfused Kidneys with LPNPY.  As shown in the left panel of 
figure 3.1, Ang II caused a significant concentration-dependent (0.3, 1 and 3 nmoles/L) increase 
in renal perfusion pressure in WKY.  Ang II also caused a significant concentration-dependent 
increase in renal perfusion pressure in SHR kidneys (figure 3.1, right panel).  Ang II-induced 
increases in renal perfusion pressure were significantly greater in SHR compared with WKY 
kidneys (right versus left panels in figure 3.1).  In SHR kidneys, and at all concentrations of Ang 
II, LPNPY significantly potentiated Ang II-induced increases in renal perfusion pressure (figure 
3.1, left panel).  In contrast, in WKY kidneys, LPNPY did not augment Ang II-induced increases 
in renal perfusion pressure regardless of the concentration of Ang II (figures 3.1, right panel).  
Two-factor analysis of variance demonstrated a significant interaction between rat strain and 
LPNPY on Ang II-induced changes in perfusion pressure (P=0.003, P<0.001 and P=0.004 for 
0.3, 1 and 3 nmoles/L Ang II, respectively). 
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FIGURE 3.1  
Absolute change in perfusion pressure of isolated, perfused kidneys following infusion of 
Ang II (final concentration of 0.3, 1, and 3 nmoles/L, respectively) in the absence (Basal) and 
presence of LPNPY (final concentration of  10 nmoles/L) in WKY (left panel) and SHR (right 
panel) kidneys.  “a” indicates significantly different (Fisher’s LSD test) within strain comparing 
without and with LPNPY.  “b” indicates significantly different (Fisher’s LSD test) between 
strains at same level of LPNPY.  Values are means ± SEM. 
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 In a separate set of experiments, in naïve SHR kidneys LPNPY again markedly and 
significantly potentiated the ability of Ang II (0.3 nmoles/L) to increase renal perfusion pressure 
(figure 3.2A).  The ability of LPNPY to potentiate Ang II-induced renal vasoconstriction was 
abrogated by BIBP3226 (figure 3.2B,D) and pertussis toxin (figure 3.2C,D).  Moreover, Ang II-
induced renal vasoconstriction was significantly attenuated by BIBP3226 and pertussis toxin 
even in the absence of LPNPY (compare basal responses to Ang II in A and B/C graphs of figure 
3.2).  
     
RT-PCR for Y1 Receptor mRNA and Western Blotting for Y1 Receptor Protein.  As 
shown in Figure 3.3, mRNA and protein expression for Y1 receptors was detected in whole 
kidney and PGMVs from both WKY and SHR.  However, the expression of Y1-receptor mRNA 
and protein when normalized to beta-actin and quantified by densitometry did not differ between 
WKY and SHR tissues (Figure 3.4). 
  
Experiments in Isolated, Perfused Kidneys with PYY3-36.   As shown in figure 3.5A, 
PYY3-36 caused a very small, but statistically significant and reproducible, potentiation of Ang 
II-induced renal vasoconstriction (P=0.0014).  However, in WKY, PYY3-36 did not significantly 
alter Ang II-induced renal vasoconstriction (data not shown).  The difference in Ang II-induced 
renovascular changes in SHR versus WKY was statistically significant (P= 0.0017). 
As shown in figures 3.5B and 3.5C, respectively, BIIE0246 and pertussis toxin 
completely blocked PPY3-36-induced potentiation of Ang II-induced changes in perfusion 
pressure.  Consistent with our previous experiments, Ang II-induced renal vasoconstriction was 
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FIGURE 3.2 
 Absolute change in perfusion pressure of isolated, perfused kidneys after infusion of Ang 
II (final concentration in the perfusate of 0.3 nmol/L) in the absence (Basal) and presence of 
LPNPY (final concentration in the perfusate of 6 nmol/L) in untreated SHR kidneys (A), in SHR 
kidneys pretreated with BIBP3226 (1 µmol/L; B), and in kidneys obtained from SHR pretreated 
with intravenous pertussis toxin 3 days before removing the kidney for perfusion (C). D  
illustrates the enhancement of Ang II–induced changes in perfusion pressure by LPNPY in 
control, BIBP3226-treated and pertussis toxin–treated kidneys. In A, B, and C, “a” indicates 
significant difference (Student t test) comparing without and with LPNPY. In D, “a” indicates  
significant difference between BIBP3226 and control and pertussis toxin and control (Fisher 
LSD  test). Values are mean ± SEM. 
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FIGURE 3.3 
RT-PCR products for Y1 receptor mRNA and beta-actin mRNA in WKY and SHR 
kidneys (top panel left) and in preglomerular microvessels (PGMV; bottom panel left). Western 
blot analysis of Y1 receptor and beta-actin in WKY and SHR kidneys (top panel right) and 
preglomerular microvessels (PGMV; bottom panel right). 
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FIGURE 3.4 
Top panels:  Densitometry results (normalized to beta-actin signal) from Western blot 
analysis of Y1 receptor mRNA in WKY versus SHR kidneys (left panel) and preglomerular 
microvessels (PGMV; right panel).  Bottom panels:  Densitometry results (normalized to beta-
actin signal) from RT-PCR products for Y1 receptor mRNA in WKY versus SHR kidneys (left 
panel) and preglomerular microvessels (PGMV; right panel). 
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significantly attenuated by pertussis toxin even in the absence of PYY3-36 (compare basal 
responses to Ang II in figures 3.5A versus 3.5C). 
 
RT-PCR for Y2 Receptor mRNA and Western Blotting for Y2 Receptor Protein.  As 
shown in figure 3.6, mRNA and protein expression for Y2 receptors was detected in whole 
kidney and PGMVs from both WKY and SHR.  However, the expression of Y2 receptor mRNA 
and protein when normalized to beta-actin and quantified by densitometry did not differ between 
WKY and SHR tissues (data not shown). 
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FIGURE 3.5 
 Absolute change in perfusion pressure of isolated, perfused kidneys after infusion of Ang  
II (final concentration in the perfusate of 0.3 nmol/L) in the absence (Basal) and presence of  
PYY3-36 (final concentration in the perfusate of 6 nmol/L) in untreated SHR kidneys (A), in SHR 
kidneys pretreated with BIIE0246 (1 µmol/L; B), and in kidneys obtained from SHRs  pretreated 
with intravenous pertussis toxin 3 days before removing the kidney for perfusion (C).  D 
illustrates the enhancement of Ang II–induced changes in perfusion pressure by PYY3-36 in 
control, BIIE0246-treated, and pertussis toxin–treated kidneys. In A, B, and C, “a” indicates 
significant difference (Student t test) comparing without and with PYY3-36. In D, “a” indicates 
significant difference between BIIE0246 and control and pertussis toxin and control (Fisher LSD  
test). Values are mean ± SEM.  
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FIGURE  3.6 
RT-PCR products for Y2 receptor mRNA and beta-actin mRNA in WKY and SHR 
kidneys (top panel right) and in preglomerular microvessels (PGMV; bottom panel right). 
Western blot analysis of Y2 receptor and beta-actin in WKY and SHR kidneys (top panel left) 
and preglomerular microvessels (PGMV; bottom panel left). 
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3.3 Summary 
  
 The results in chapter three focus on the role of the Y1 and Y2 receptors’ ability to 
augment Ang II induced renal vasoconstriction. In this respect LPNPY, a highly selective Y1 
receptor agonist, greatly enhances the renovascular responses to Ang II in the SHR kidney, yet 
does not potentiate responses to Ang II in the WKY kidney.  Moreover, our findings demonstrate 
that this effect is dependent on an intact Y1-Gi pathway.  In this regard, we observe two findings:  
First, BIBP3226, a highly selective Y1 receptor antagonist, blocks the ability of LPNPY to 
enhance renovascular responses to Ang II, and second, pertussis toxin, a toxin that ADP 
ribosylates Gi rendering it inactive, blocks the ability of LPNPY to enhance renovascular 
responses to Ang II. 
 The results of the present study also indicate that Y2 receptor activation (via PYY3-36) 
also enhances renal vasoconstrictor responses to Ang II in SHR but not WKY.  While this effect 
is much smaller compared to the effect observed from Y1 receptor activation, the observed 
potentation is also dependent on an intact Y2-Gi pathway.  In this regard, BIIE0246, a highly 
selective Y2 antagonist, completely abrogates the ability of PYY3-36 to enhance Ang II-induced 
renal vasoconstriction.  Similarily, pertussis toxin abolishes the effect observed with Y2 
activation alone. 
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CHAPTER 4 
Naturally-Occurring PP-Fold Peptides Enhance Angiotensin II-Induced 
Renal Vasoconstriction:  Interaction With α2-Adrenoceptors 
 
4.1 Introduction 
 Our recent study (chapter 3) indicates that the selective, synthetic Y1-receptor agonist 
LPNPY greatly enhances Ang II-induced changes in renovascular resistance in isolated, perfused 
kidneys from SHR, but not in kidneys from normotensive WKY rats.  Moreover, this interaction 
is abolished by the selective Y1-receptor antagonist BIBP3226 and is mediated by the Gi signal 
transduction pathway. These findings would suggest that perhaps naturally-occurring, 
endogenous Y1-receptor agonists facilitate Ang II-induced renal vasoconstriction in genetic 
hypertension. 
The only known naturally-occurring, endogenous agonists of Y1 receptors are NPY and 
PYY.[25] NPY is released within the kidney from renal sympathetic nerves directly into the 
neuroeffector junction between renal sympathetic varicosities and renal vascular smooth muscle 
cells, and therefore would have ready access to renovascular smooth muscle cells responsive to 
Ang II.[21] Although not released from sympathetic varicosities, PYY is secreted into the 
systemic circulation from intestinal enterocytes in response to food intake.[25] Thus PYY would 
also be expected to circulate to the kidney and be available to activate Y1 receptors in the renal 
microcirculation. 
The above discussion supports the hypothesis that both NPY and PYY potentially could 
play a role with regard to enhancing Ang II-induced renal vasoconstriction in genetic 
hypertension.  However, the effects of NPY and PYY on Ang II-induced renal vasoconstriction 
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in kidneys from genetically hypertensive animals are unknown. Therefore, the primary goal of 
this chapter was to determine and compare the effects of NPY and PYY on renovascular 
responses to Ang II in isolated, perfused kidneys obtained from SHR, and to determine the role 
of Y1 receptors in the effects of NPY and PYY on Ang II renovascular responses. 
As mentioned in the introduction, PYY is cleaved by DPPIV to PYY3-36, which is another 
naturally-occurring PP-fold peptide.[36,37]  Unlike NPY and PYY which bind to and activate 
Y1, Y2 and Y5 receptors, PYY3-36 is selective for Y2 receptors.[25] Our previous results indicate 
that Y2-receptor activation only slightly potentiates Ang II-induced renal vasoconstriction in 
kidneys from genetically hypertensive animals, and not at all in kidneys from normotensive rats. 
This suggests that intestinal processing of PYY to PYY3-36 may importantly determine the effects 
of the PYY system on renovascular responses to Ang II in kidneys from genetically hypertensive 
rats (further explored in chapter 6). However, a direct comparison between PYY3-36 and PYY on 
renovascular response to Ang II in kidneys from genetically hypertensive rats is lacking. 
Therefore the second objective of this chapter was to determine and compare the effects of 
PYY3-36 and PYY on renovascular responses to Ang II in isolated, perfused kidneys obtained 
from spontaneously hypertensive rats. 
Catecholamines can activate α2-adrenoceptors, and like Y1 receptors, α2-adrenoceptors 
are also coupled to Gi proteins. Thus it is not surprising that α2-adrenoceptor activation, like Y1-
receptor activation, facilitates Ang II-induced renal vasoconstriction in the genetically 
hypertensive kidney as shown in figures 1.2a/b.[20,59,60]  Because α2-adrenoceptors and Y1 
receptors both couple to Gi proteins, it is conceivable that sub-threshold/near-threshold 
activation of α2-adrenoceptors synergize with PP-fold peptides with regard to enhancing 
renovascular responses to Ang II in kidneys from genetically hypertensive rats. Renal vascular 
 
42
smooth muscle cells are bathed with catecholamines released from renal sympathetic nerves and 
are simultaneously under the influence of PP-fold peptides. Accordingly, a third objective of this 
chapter was to determine whether a sub-threshold concentration of the α2-adrenoceptor agonist 
UK14304 plus a sub-threshold concentration of either NPY, PYY or PYY3-36 would enhance 
renovascular responses to Ang II in isolated, perfused kidneys obtained from spontaneously 
hypertensive rats. 
Indeed, we did observe a synergy between UK14,304 and NPY and UK14,304 and PYY, 
but not UK14,304 and PYY3-36, suggesting that the synergy between the α2-adrenoceptor agonist 
and the PP-fold peptides was mediated via the Y1 receptor. To confirm this, we also examined 
the interaction between a sub-threshold dose of UK14,304 and a sub-threshold dose of LPNPY 
(selective Y1-receptor agonist) on Ang II-induced renal vasoconstriction. This latter study was 
conducted in vivo to ensure that the synergy was not an artifact of the isolated, perfused kidney 
and was performed in kidneys from both SHR and WKY to determine whether the synergy was 
restricted to kidneys from genetically hypertensive rats. 
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 4.2 Results 
 Experiments in Isolated, Perfused Kidneys. The average baseline renal perfusion 
pressure in all 98 kidney perfusion experiments was 54 ± 2 mm Hg, and was not affected by any 
of the various treatments or combinations of treatments. Although the perfusion flow rate was 
physiological (5 ml/min), baseline perfusion pressures were below the normal renal perfusion 
pressure in vivo because of the low viscosity of Tyrode’s solution compared with whole blood. 
However, despite the low basal perfusion pressure, the kidneys were very responsive to Ang II. 
As shown in figure 4.1, Panel A, 0.1 nmoles/L of NPY did not potentiate renovascular responses 
to Ang II. Although 1 nmoles/L of NPY did significantly enhance renovascular responses to Ang 
II, this effect was barely detectable and represented a concentration of NPY that was low enough 
to only mildly effect Ang II responses (figure 4.1, Panel B). In contrast, 6 nmoles/L of NPY 
more than doubled the renovascular response to Ang II (figure 4.1, Panel C). Higher 
concentrations of NPY were not examined because although concentrations equal to or less than 
6 nmoles/L did not change baseline perfusion pressure, higher concentrations did. As shown in 
figure 4.1, Panel D, in kidneys treated with BIBP3226, 6 nmoles/L of NPY only slightly 
augmented renovascular responses to Ang II, and this effect was not statistically significant. 
Although our previously published studies demonstrated that 10 nmoles/L of UK14,304 
augmented renovascular responses to 10 nmoles/L of Ang II, as shown in figure 4.1, Panel E, 10 
nmoles/L of UK14,304 did not enhance renovascular responses to a very low concentration of 
Ang II (0.3 nmoles/L). However, when a sub-threshold concentration of UK14,304 (10 
nmoles/L) was combined with a near-threshold concentration of NPY (1 nmole/L) a significant 
 
44
potentiation of the renovascular response to Ang II was observed. These results are represented 
differently in figure 4.2 which  
 
 
 
 
 
FIGURE 4.1 
 Bar graph illustrating the effects of neuropeptide Y (NPY) at 0.1 (Panel A), 1 (Panel B) 
and 6 (Panel C) nmoles/L on vasoconstrictor responses (change in perfusion pressure) to 
angiotensin II (Ang II; 0.3 nmoles/L) in isolated, perfused kidneys obtained from spontaneously 
hypertensive rats.  Also shown are the effects of NPY at 6 nmoles/L in combination with the Y1-
receptor antagonist BIBP3226 (BIBP; 1 µmole/L) (Panel D) and the effects of the α2-
adrenoceptor agonist UK14,304 (10 nmoles/L) alone (Panel E) and in combination with 1 
nmoles/L of NPY (Panel F).  Values are means ± SEM. aP<0.05 compared with basal (2-tailed 
paired Student’s t-test). 
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illustrates the difference in response to Ang II before and after the various treatments. As 
indicated, the enhancement of Ang II-induced change in perfusion pressure was greater in 
kidneys treated with either 6 nmoles/L of NPY or 1 nmoles/L of NPY + 10 nmoles/L of 
UK14,304 compared with all other groups. 
As shown in figure 4.3, Panel A, 0.1 nmoles/L of PYY1-36 did not potentiate renovascular 
responses to Ang II. Although 1 nmoles/L of PYY1-36 did significantly enhance renovascular 
responses to Ang II, this effect was barely detectable and represented a near-threshold 
concentration of PYY1-36 (Figure 4.3, Panel B). In contrast, 6 nmoles/L of PYY1-36 more than 
doubled the renovascular response to Ang II (Figure 4.3, Panel C). As with NPY, higher 
concentrations of PYY1-36 were not examined because although concentrations equal to or less 
than 6 nmoles/L did not change baseline perfusion pressure, higher concentrations did. As shown 
in Figure 4.3, Panel D, in kidneys treated with BIBP3226, 6 nmoles/L of PYY1-36 only slightly 
augmented renovascular responses to Ang II. When a sub-threshold concentration of UK14,304 
(10 nmoles/L) was combined with a near-threshold concentration of PYY1-36 (1 nmole/L) a 
potentiation of the renovascular response to Ang II was observed (figure 4.3, Panel F). These 
results are represented differently in figure 4.4 which illustrates the difference in response to 
Ang II before and after the various treatments. As indicated, the enhancement of Ang II-induced 
change in perfusion pressure was greater in kidneys treated with either 6 nmoles/L of PYY1-36 or 
1 nmoles/L of PYY1-36 + 10 nmoles/L of UK14,304 compared with all other groups. 
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FIGURE 4.2 
 Enhancement of angiotensin II (Ang II)-induced change in perfusion pressure in isolated, 
perfused kidneys obtained from spontaneously hypertensive rats by 0.1, 1 and 6 nmoles/L of 
neuropeptide Y (NPY), by 6 nmoles/L of NPY in the presence of the Y1-receptor antagonist 
BIBP3226 (BIBP; 1 µmole/L), by the α2-adrenoceptor agonist UK14304 (10 nmoles/L) and by 
UK14,304 in combination with 1 nmoles/L of NPY.  Values are means ± SEM.  aP<0.05 
compared with basal (Fisher’s least signficant difference test). 
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FIGURE 4.3 
 Bar graph illustrating the effects of peptide YY1-36 (PYY1-36) at 0.1 (Panel A), 1 (Panel B) 
and 6 (Panel C) nmoles/L on vasoconstrictor responses (change in perfusion pressure) to 
angiotensin II (Ang II; 0.3 nmoles/L) in isolated, perfused kidneys obtained from spontaneously 
hypertensive rats.  Also shown are the effects of PYY1-36 at 6 nmoles/L in combination with the 
Y1-receptor antagonist BIBP3226 (BIBP; 1 µmole/L) (Panel D) and the effects of the α2-
adrenoceptor agonist UK14,304 (10 nmoles/L) alone (Panel E) and in combination with 1 
nmoles/L of PYY1-36 (Panel F).  Values are means ± SEM. aP<0.05 compared with basal (2-
tailed paired Student’s t-test). 
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FIGURE 4.4 
 Enhancement of angiotensin II (Ang II)-induced change in perfusion pressure in isolated, 
perfused kidneys obtained from spontaneously hypertensive rats by 0.1, 1 and 6 nmoles/L of 
peptide YY1-36 (PYY1-36), by 6 nmoles/L of PYY1-36 in the presence of the Y1-receptor antagonist 
BIBP3226 (BIBP; 1 µmole/L), by the α2-adrenoceptor agonist UK14304 (10 nmoles/L) and by 
UK14,304 in combination with 1 nmoles/L of PYY1-36.  Values are means ± SEM.  aP<0.05 
compared with basal (Fisher’s least signficant difference test). 
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As shown in figure 4.5, neither 0.1 (Panel A) nor 1 (Panel B) nmoles/L of PYY3-36 
potentiated renovascular responses to Ang II. Even 6 nmoles/L of PYY3-36 only very slightly, but 
reproducibly, enhanced the renovascular response to Ang II (Figure 4.5, Panel C). As shown in 
figure 4.5, Panel D, treatment with BIIE0246 (1 µmole/L) abolished the ability of PYY3-36 (6 
nmoles/L) to augment renovascular responses to Ang II. When a sub-threshold concentration of 
UK14,304 (10 nmoles/L) was combined with a sub-threshold concentration of PYY3-36 (1 
nmole/L) no potentiation of the renovascular response to Ang II was observed (figure 4.5, Panel 
F). These results are represented differently in figure 4.6 which illustrates the difference in 
response to Ang II before and after the various treatments. As indicated, the enhancement of Ang 
II-induced change in perfusion pressure was greater in kidneys treated with either 6 nmoles/L of 
PPY3-36 compared with all other groups.  
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FIGURE 4.5 
 Bar graph illustrating the effects of peptide YY3-36 (PYY3-36) at 0.1 (Panel A), 1 (Panel B) 
and 6 (Panel C) nmoles/L on vasoconstrictor responses (change in perfusion pressure) to 
angiotensin II (Ang II; 0.3 nmoles/L) in isolated, perfused kidneys obtained from spontaneously 
hypertensive rats.  Also shown are the effects of PYY3-36 at 6 nmoles/L in combination with the 
Y1-receptor antagonist BIIE0246 (BIIE; 1 µmole/L) (Panel D) and the effects of the α2-
adrenoceptor agonist UK14,304 (10 nmoles/L) alone (Panel E) and in combination with 1 
nmoles/L of PYY3-36 (Panel F).  Values are means ± SEM. aP<0.05 compared with basal (2-
tailed paired Student’s t-test). 
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FIGURE 4.6 
 Enhancement of angiotensin II (Ang II)-induced change in perfusion pressure in isolated, 
perfused kidneys obtained from spontaneously hypertensive rats by 0.1, 1 and 6 nmoles/L of 
peptide YY3-36 (PYY3-36), by 6 nmoles/L of PYY3-36 in the presence of the Y2-receptor antagonist 
BIIE0246 (BIIE; 1 µmole/L), by the α2-adrenoceptor agonist UK14304 (10 nmoles/L) and by 
UK14,304 in combination with 1 nmoles/L of PYY3-36.  Values are means ± SEM.  aP<0.05 
compared with basal (Fisher’s least signficant difference test). 
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Experiments in Kidneys In Vivo. In WKY, baseline RVRs in control, UK14,304- treated, 
LPNPY-treated and UK14,304 plus LPNPY-treated rats were 11 ± 1, 11 ± 1, 15 ± 2 and 11 ± 1 
mm Hg/(ml/min per gram kidney weight), respectively (no significant differences among four 
groups). In SHR, baseline RVRs in control, UK14,304-treated, LPNPY-treated and UK14,304 
plus LPNPY-treated rats were 16 ± 2, 18 ± 2, 18 ± 4 and 22 ± 3 mm Hg/(ml/min per gram kidney 
weight), respectively (no significant differences among four groups). Baseline RVRs were 
greater in SHR compared with WKY (P<0.0001). Ang II increased RVR in both WKY and SHR 
kidneys (Figure 4.7). Due to careful selection of sub-threshold doses, treatment with UK14,304 
by itself and treatment with LPNPY by itself did not enhance Ang II-induced changes in RVR. 
However, treatment with UK14,304 plus LPNPY significantly enhanced Ang II-induced 
increases in RVR in both WKY and SHR (Figure 4.7); however, the potentiation of Ang II-
induced increases in RVR by UK 14,304 plus LPNPY was greater in SHR compared with WKY 
kidneys (Figure 4.7).   
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FIGURE 4.7 
 Absolute change in renal vascular resistance (RVR; n=7) in vivo following infusion of 
Ang II (10 ng/kg per minute) plus low doses of UK14,304 (UK; 0.3 µg/kg/min), [Leu31,Pro34]-
neuropeptide Y (LPNPY; 1 µg/kg/min) or UK14,304 plus LPNPY (UK+LPNPY).  All 
statistically significant differences are noted with S (Fisher’s LSD test).  Values are means ± 
SEM. 
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4.3 Summary 
  
 The present study, chapter four, illustrates the potential of endogenous PP-fold peptides 
to potentiate renovascular responses in genetic hypertension.   Although all PP-fold peptides 
were investigated, PYY3-36 demonstrated little to no ability to alter renovascular responses at 
concentrations closer to physiological relevance.  PYY3-36 also revealed no potential to synergize 
with alternative agonist for Gi, namely UK14,304.  Alternatively, in vitro in our perfusion 
system, the threshold concentration of naturally occurring PP-fold Y1-receptor agonists for 
enhancing the responses to Ang II is equal to or less than 1 nmole/L.  This concentration would 
be considered an upper limit for the in vivo threshold concentration because small peptides 
commonly bind tightly to various surfaces.   Thus it is likely that in the transit from the infusion 
catheter, through the warming coil and through the bubble trap of our kidney perfusion system 
that these low concentrations of peptides were rendered even lower by binding of the peptides to 
surfaces.  The actual concentrations reaching the kidney were most likely much lower.  In 
general, sympathetic nerve terminals release NPY directly onto vascular smooth muscle, and 
thus it seems likely that such concentrations (1 nmole/L) would be achieved locally with 
elevated renal sympathetic tone; however, direct evidence for this concept is not available.  In 
rats, systemic levels of PYY can reach 0.1 nmoles/L to 0.25 nmoles/L.[43]  This concentration is 
only 10 to 20% of the in vitro threshold concentration required for potentiation after a few 
minutes of exposure, it is conceivable that over longer periods of time, even these lower 
concentrations could potentiate responses to Ang II in kidneys from genetically-susceptible 
animals and human beings. 
 In relation to the above idea, the present study further shows that low-level stimulation of 
α2-adrenoceptor synergizes with threshold concentrations of NPY and PYY to potentiate 
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renovascular responses to Ang II in isolated, perfused kidneys from SHR.  These findings are 
significant because the renal vasculature is simultaneously under the influence of circulating PP-
fold peptides and catecholamines released from renal sympathetic nerves.  In order to 
demonstrate that these findings are not due to an artifact of our in vitro system, we also show 
that selective Y1 receptor activation with LPNPY and selective α2-adrenoceptor stimulation with 
UK 14,304 leads to a robust renovascular response to Ang II in kidneys from genetically 
hypertensive animals compared to normotensive animals. 
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CHAPTER 5 
Modulation of Angiotensin II-Induced Renal Vasoconstriction by 
Renal Sympathetic Nerves: Role of Y1-Receptor/Gi-Protein Pathway 
 
 
 
5.1 Introduction 
 Our recent studies reveal yet another potential mode of interaction between the renal 
sympathetic nervous system and the renin-angiotensin system, particularly in animals with 
genetic hypertension.  In this regard, chapter 4 demonstrates that activation of renal vascular α2-
adrenoceptors with UK 14,304 or renal vascular Y1 receptors with either exogenous NPY or 
exogenous PYY1-36 enhances Ang II-induced increases in renal vascular resistance in kidneys 
from SHR but not in kidneys from WKY[12,59,60,62].  Our previous studies also demonstrate 
that inhibiting the Gi signal transduction pathway with pertussis toxin blocks the ability of UK 
14,304 and NPY to augment Ang II-induced renal vasoconstriction in SHR kidneys, indicating 
that in SHR kidneys both α2-adrenoceptors and Y1 receptors modulate Ang II-induced renal 
vasoconstriction via the Gi signal transduction pathway [12,60].  Moreover, our studies  in 
chapter four show that in SHR kidneys very low concentrations of UK 14,304, NPY or PYY1-36, 
that do not per se enhance renal vascular responses to Ang II, potentiate Ang II-induced renal 
vasoconstriction when combined (i.e., UK 14,304 + NPY or UK 14,304 + PYY1-36).  This 
suggests a synergy between agonists of the Gi pathway so that low concentrations of distinct 
ligands acting on their cognate receptors can augment Ang II-induced renal vasoconstriction in 
SHR kidneys by their combined effects of the Gi signal transduction pathway.  
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 The importance of the aforementioned observations is that renal sympathetic nerves co-
release an α2-adrenoceptor agonist (i.e., norepinphrine) and a Y1 receptor agonist (i.e., NPY) 
[21]. Therefore, it is conceivable that endogenous neurotransmitters released from renal 
sympathetic nerves modulate, either separately or synergistically, Ang II-induced renal 
vasoconstriction in SHR kidneys by activating the Gi pathway.  The purpose of this chapter was 
to test this hypothesis. 
 
5.2 Results 
 
 Basal Renal Perfusion Pressures. As shown in Table 5.1, MABPs were significantly 
higher in SHR compared to WKY, and pretreatment with pertussis toxin significantly reduced 
MABP in SHR.  Heart rates and basal renal perfusion pressures, either before or after prazosin, 
were similar among all ten groups.  Sham RNS did not affect renal perfusion pressure, and actual 
RNS did not affect renal perfusion pressure in the presence of prazosin because prazosin blocked 
α1-adrenoceptor-induced vasoconstriction. 
 
 Renal Nerve Stimulation in Isolated, Perfused Kidneys of WKY. Figure 5.1 
demonstrates the lack of effect of RNS on renovascular responses to Ang II in WKY kidneys.  
During P1, a physiological concentration of Ang II (100 pmoles/L) increased renal perfusion 
pressure by 1.6 ± 0.2 mm Hg in WKY kidneys.  This response to Ang II did not change during 
P2 or P3 in either the sham RNS group or the actual RNS group. 
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 Renal Nerve Stimulation in Isolated, Perfused Kidneys of SHR.  Figure 5.2 illustrates 
the ability of RNS to enhance renovascular response to Ang II in SHR kidneys.  During P1, Ang 
II (100 pmoles/L) increased renal perfusion pressure by 8.6 ± 0.7 mm Hg in SHR kidneys.  This 
response to Ang II did not change during P2 or P3 in the sham RNS group; however, in the 
actual RNS group, the response to Ang II was increased to 135  ± 9% and 177 ± 26% 
(normalized to the P1 response) (P<0.05). 
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Table 5.1: Mean arterial blood pressures and renal perfusion pressures. 
aIndicates significantly different than SHR; bIndicates significantly different than SHR not 
treated with PT. Values are means and standard errors for 7 kidneys in all groups except the PT 
groups in which n=5. 
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FIGURE 5.1 
 Lack of effect of periarterial renal nerve stimulation (RNS) or sham RNS (SHAM) on 
vasoconstrictor responses (change in renal perfusion pressure in a constant flow system) to 
angiotensin II (Ang II; 100 pmoles/L) in isolated, perfused kidneys obtained from normotensive 
Wistar-Kyoto (WKY) rats.  The responses to Ang II during the second (P2) and third (P3) 
experimental periods were normalized to the responses during the control first period (P1). 
Values are means ± SEM. 
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FIGURE 5.2 
  
 Periarterial renal nerve stimulation (RNS) enhances vasoconstrictor responses (change in 
renal perfusion pressure in a constant flow system) to angiotensin II (Ang II; 100 pmoles/L) in 
isolated, perfused kidneys obtained from spontaneously hypertensive rats (SHR).  The responses 
to Ang II during the second (P2) and third (P3) experimental periods were normalized to the 
responses during the control first period (P1).  Some kidneys were exposed only to sham RNS 
(SHAM).  Values are means ± SEM. *Indicates P<0.05 (unpaired Student’s t-test) for RNS 
versus SHAM at the indicated experimental period. 
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Figure 5.3 shows that the ability of RNS to enhance renovascular response to Ang II in 
SHR kidneys is not blocked by rauwolscine, a highly potent and selective α2-adrenoceptor 
antagonist.  In kidneys pretreated with rauwolscine, during P1, Ang II (100 pmoles/L) increased 
renal perfusion pressure by 6.3 ± 0.7 mm Hg in SHR kidneys.  This response to Ang II did not 
change during P2 or P3 in the sham RNS group; however, in the actual RNS group, the response 
to Ang II was increased to 132  ± 9% and 147 ± 7% (normalized to the P1 response) (P<0.05). 
 Figure 5.4 demonstrates that the ability of RNS to enhance renovascular response to Ang 
II in SHR kidneys is completely abrogated by BIBP3226, a highly selective and potent Y1-
receptor antagonist.  In kidneys pretreated with BIBP3226, during P1, Ang II (100 pmoles/L) 
increased renal perfusion pressure by 7.6 ± 0.7 mm Hg in SHR kidneys.  This response to Ang II 
did not change during P2 or P3 in either the sham RNS group or the actual RNS group. 
 Figure 5.5 demonstrates that the ability of RNS to enhance renovascular response to Ang 
II in SHR kidneys is completely abrogated by pertussis toxin, a toxin that ADP ribosylates Gi 
proteins and thereby inhibits signaling via Gi proteins.  In kidneys obtained from SHR pretreated 
with pertussis toxin, during P1, Ang II (100 pmoles/L) increased renal perfusion pressure by 7.6 
± 0.7 mm Hg in SHR kidneys.  This response to Ang II did not change during P2 or P3 in either 
the sham RNS group or the actual RNS group.  
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FIGURE 5.3 
 Periarterial renal nerve stimulation (RNS) enhances vasoconstrictor responses (change in 
renal perfusion pressure in a constant flow system) to angiotensin II (Ang II; 100 pmoles/L) in 
isolated, perfused kidneys obtained from spontaneously hypertensive rats (SHR) and that were 
pretreated with the α2-adrenoceptor antagonist rauwolscine (10 nmoles/L).  The responses to 
Ang II during the second (P2) and third (P3) experimental periods were normalized to the 
responses during the control first period (P1).  Some kidneys were exposed only to sham RNS 
(SHAM).  Values are means ± SEM. *Indicates P<0.05 (unpaired Student’s t-test) for RNS 
versus SHAM at the indicated experimental period. 
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FIGURE 5.4 
 Periarterial renal nerve stimulation (RNS) does not enhance vasoconstrictor responses 
(change in renal perfusion pressure in a constant flow system) to angiotensin II (Ang II; 100 
pmoles/L) in isolated, perfused kidneys obtained from spontaneously hypertensive rats (SHR) 
and that were pretreated with the Y1-adrenoceptor antagonist BIBP3226 (1 µmoles/L).  The 
responses to Ang II during the second (P2) and third (P3) experimental periods were normalized 
to the responses during the control first period (P1).  Some kidneys were exposed only to sham 
RNS (SHAM).  Values are means ± SEM. 
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FIGURE 5.5 
 Periarterial renal nerve stimulation (RNS) does not enhance vasoconstrictor responses 
(change in renal perfusion pressure in a constant flow system) to angiotensin II (Ang II; 100 
pmoles/L) in isolated, perfused kidneys obtained from spontaneously hypertensive rats (SHR) 
and that were pretreated three days prior to the perfusion experiment with an intravenous 
injection of pertussis toxin (30 µg/kg).  The responses to Ang II during the second (P2) and third 
(P3) experimental periods were normalized to the responses during the control first period (P1).  
Some kidneys were exposed only to sham RNS (SHAM).  Values are means ± SEM. 
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5.3 Summary 
  
   Our results in chapter five demonstrate the natural role of the PP-fold Y1 peptide 
receptors ability to augment renal response in the SHR.  In this respect, our findings reveal that a 
physiological level (5 Hz) of stimulation of the renal periarterial nerves, results in a near 
doubling of the renovascular response to a physiological level (100 pmoles/L) of Ang II in 
kidneys from SHR.  In contrast, in kidneys from WKY rats, periarterial nerve stimulation does 
not significantly alter vasoconstrictor responses to Ang II.   Although periarterial nerve 
stimulation results in the release of multiple neurotransmitters, namely catecholamines and NPY, 
specific antagonists were used to specify which released neurotransmitters were most likely 
altering renal vascular responses to Ang II in SHR.  The results of the present study show that 
blockade of Gi with pertussis toxin abolishes the ability of renal sympathetic nerve stimulation to 
enhance renovascular responses to Ang II in SHR kidneys.  This finding indicates that renal 
sympathetic nerve stimulation augments renovascular responses to Ang II in SHR kidneys via a 
Gi signal transduction pathway, similarly as our previous results.   
 Our previous studies, chapter 4, show that activation of the Gi pathway by agonists of α2-
adrenoceptors or Y1 receptors or by co-activation of both α2-adrenoceptors and Y1 receptors 
potentiates renovascular response to Ang II in SHR kidneys.  Because renal sympathetic nerves 
release both norepinephrine and NPY, which activate α2-adrenoceptors and Y1 receptors, 
respectively, we anticipated that the ability of renal sympathetic nerve stimulation to augment 
renovascular responses to Ang II would be attenuated somewhat by both rauwolscine (an α2-
adrenoceptor antagonist) and BIBP 3226 (a Y1 receptor antagonist), but not completely by either.  
In contrast to our expectations, rauwolscine did not significantly affect the ability of renal 
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sympathetic nerve stimulation to augment renovascular responses to Ang II, whereas BIBP3226 
completely abrogated stimulation-induced enhancement of Ang II responses. 
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 CHAPTER 6 
Blockade Of PYY Conversion To PYY3-36 Via Dipeptidyl Peptidase IV 
Increases Arterial Blood Pressure in SHR 
 
6.1 Introduction  
 PYY1-36 is cleaved by dipeptidyl peptidase IV to PYY3-36.  However, unlike NPY and 
PYY1-36 that bind to and activate Y1 receptors, PYY3-36 is highly selective for Y2 receptors.[25]  
Previous results described in chapter three indicate that Y2-receptor activation only slightly 
potentiates Ang II-induced renal vasoconstriction in kidneys from genetically hypertensive 
animals.  This finding reveals the possibility that the catalytic conversion of PYY to PYY3-36  
may play a role in protecting against constant exposure of Y1 receptor activation which 
demonstrated the ability to significantly potentiate renovascular responses to Ang II.  This idea 
was further confirmed and extended in chapter four by the observations that compared to either 
NPY or PYY1-36, PYY3-36 has much less ability to enhance renovascular responses to Ang II.  In 
addition, PYY3-36 had no ability to synergize with an alternative Gi agonist, namely UK14,304, to 
augment renal vascular responses.  The implication of these finding is that conversion of PYY1-36 
to PYY3-36 may determine the net effects of the PYY on the cardiovascular and renal systems in 
genetically hypertensive rats.   
 Inhibitors of dipeptidyl peptidase IV are being developed for the treatment of type 2 
diabetes, as mentioned in the introduction.[51-55].  This treatment may beneficially decrease 
blood glucose via GLP activation, but this type of treatment would also be expected to prevent 
the proteolytic cleavage of PYY1-36 to PYY3-36.   It is, thus, conceivable that in some patients, 
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inhibitors of dipeptidyl peptidase IV could adversely affect renal function and arterial blood 
pressure by raising PYY1-36 levels.  Chapter six focuses on the overall effects of inhibition of 
dipeptidyl peptidase IV on arterial blood pressure. 
 
6.2 Results 
 
 Basal Mean Arterial Blood Pressures. MABP were significantly higher in SHR 
compared to WKY animals following a one-hour rest period and an injection of captopril to 
remove increased Ang II due to surgical stress.  Heart rates were comparable among both groups.     
. 
 
 In Vivo Experiments Monitoring MABP Following Blockade of DPPIV.  Figure 6.1 
demonstrates WKY’s lack of response to P32/98, a commercially available DPPIV inhibitor.   
Time controls reveal that saline, the P32/98 vehicle, did not significantly alter the MABP in 
WKY animals, and if anything, reveal that each iv injection resulted in a smaller response where 
the last injection had no response.  Injections of increasing concentrations of P32/98 (1, 3, 10 
mg/kg) had no significant effect on WKY HR (data not shown).   
 Figure 6.2 reveals a significant response to P32/98 by SHR.  Time controls show no 
significant response to the saline vehicle.  In contrast, SHR significantly increased 
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FIGURE 6.1 
 Change in mean arterial blood pressure (n=6) in vivo following infusion of P32/98 (1, 3, 
& 10 mg/kg per minute) or saline control in WKY. 
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FIGURE 6.2 
 Change in mean arterial blood pressure (n=10) in vivo following infusion of P32/98 (1, 3, 
& 10 mg/kg per minute) or saline control in WKY.  All statistically significant differences are 
noted with an a(vs. time control) or b(vs. smallest dose).  Values are means ± SEM. 
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MABP about 8.6  ± 2.6 mm Hg  at 3 mg/kg P32/98.  At 10 mg/kg, P32/98 also had a similar 
significant increase in MABP of 8.6  ± 4.3 mm Hg.   
 
Figure 6.3 demonstrates the extent to which P32/98 is capable of altering MABP in SHR.  
In this respect, pretreatment with BIBP3226 (40 µg/kg) blocks P32/98’s ability to potentiate 
MABP in SHR. At 3 mg/kg P32/98, where an 8.6 mm Hg increase in MABP was observed in 
SHR, BIBP pretreatment leads to a 2.1 mm Hg decrease in MABP.  At the higher concentration 
of P32/98 (10 mg/kg), BIBP pretreatment resulted in a 1.3 mm Hg increase which is markedly 
lower than the previously mentioned increase in MABP in the absence of BIBP. 
 
6.3 Summary 
 Our results in chapter six reveal the role of dipeptidyl peptidase IV to protect against 
acute increases in blood pressure in SHR.  Previous chapters reveal that physiological activation 
of the Y1-Gi signaling pathway cause a significant increase in renal vascular resistance in SHR 
while activation of the Y2-Gi has much less of a response.  DPPIV is responsible for the 
conversion of PYY to PYY3-36.[25,51-55]  As mentioned earlier, PYY has an affinity for 
primarily the Y1 receptor, and PYY3-36 has affinity only for the Y2 receptor.[25]  Therefore, we 
hypothesized that lack of DPPIV would lead to increases in PYY that would in turn lead to an 
increase in renal vascular tone, and perhaps arterial blood pressure.  Our results begin to confirm 
our hypothesis.  In this regard, P32/98, an inhibitor of DPPIV, causes a significant increase in 
mean arterial blood pressure in SHR, but not in WKY animals.  Furthermore, pretreatment with 
BIBP3226 to block the Y1-Gi signaling pathway abrogates the increase in mean arterial blood 
pressure observed in the presence of P32/98. 
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FIGURE 6.2 
 Change in mean arterial blood pressure (n=10) in vivo following infusion of P32/98 (1, 3, 
& 10 mg/kg per minute) or P32/98 + BIBP3226 (40 µg/kg)(n=6)in SHR.  Values are means ± 
SEM. 
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CHAPTER 7 
DISCUSSION 
 
7.1  Y1 And Y2 As Regulators Of Ang II Induced Renal Vasoconstriction   
 
The PP-fold family of peptides consists of four members, NPY, PYY, PYY3-36 and 
pancreatic polypeptide (PP).  Four active PP-fold peptide receptors have been cloned in primate 
species, namely Y1, Y2, Y4 and Y5 [25,34].  Although, as confirmed in chapter three, Y1 and Y2 
receptors are expressed in the kidney, Y4 and Y5 receptors are expressed predominantly in the 
intestines and brain [25], not the kidney.  Therefore, in chapter three, we focused on the role of 
Y1 and Y2 receptors as regulators of Ang II-induced renal vasoconstriction.   
 
Previous research demonstrated that SHR respond more to Ang II than WKY without 
increased Ang II receptors, Ang II concentrations, or decreased Ang II degradation.  
Furthermore, the observed increase in response to Ang II by SHR can be blocked via an inhibitor 
of Gi, and potentiated by agonists for Gi. Figure 7.1 is a schematic of view of Ang II signaling 
known at the onset of this project, and as the chapter progresses, this figure will be expanded to 
describe further the findings within this work. 
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FIGURE 7.1 
 This is a diagram of the known signaling at the start of this project.  Ang II signaling is 
more active in the SHR.  Blockade of the Gi pathway via pertussis toxin normalizes Ang II 
signaling in SHR.  Activation of the α2-adrenoreceptor-Gi pathway potentiates Ang II signaling 
in the SHR but not WKY.
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 The results of chapter three strongly support the concept that Y1 receptors enhance renal 
vasoconstrictor responses to Ang II and that the potentiation of Ang II responses by Y1 receptors 
is greater in SHR compared with WKY rats.  In this regard, our results, represented in figure 7.2, 
showed:  
1) LPNPY, a highly selective Y1-receptor agonist, greatly enhances the renovascular 
response to Ang II in the SHR kidney, yet does not potentiate responses to Ang II 
in the WKY kidney.   
2) BIBP3226, a highly selective Y1 receptor antagonist, blocks the ability of LPNPY 
to enhance renovascular responses to Ang II.  This finding confirms that the 
effects of LPNPY are mediated mostly by the Y1 receptor.   
3) Pertussis toxin, a potent blocker of the Gi, blocks the ability of LPNPY to enhance 
renovascular responses to Ang II.  This finding confirms that the effects of 
LPNPY are mediated by the Gi pathway as well. 
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FIGURE 7.2 
 This is a diagram of our primary results.  Ang II signaling is more active in the SHR.  
Activation of the Y1- Gi pathway via LPNPY, a selective Y1 agonist,  potentiates Ang II signaling 
in the SHR but not WKY.  BIBP3226 and PT block the LPNPY induced potentiation of Ang II 
signaling in SHR. 
BIBP3226 
PT 
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The results of chapter three also indicate that Y2 receptors enhance –albeit only slightly- 
renal vasoconstrictor responses to Ang II and that the potentiation of Ang II responses by Y2 
receptors is greater in SHR compared with WKY rats.  In this regard, as represented in figure 
7.3: 
1) PYY3-36, a highly selective Y2-receptor agonist, slightly enhances the 
renovascular response to Ang II in the SHR kidney, yet does not potentiate 
responses to Ang II in the WKY kidney.   
2) BIIE0246, a highly selective Y2-receptor antagonist, completely abrogates the 
ability of PYY3-36 to enhance Ang II-induced renal vasoconstriction. This effect 
confirms that the effects of PYY3-36 are mediated by the Y2 receptor and no other 
PP-fold peptide receptors.  
3) Pertussis toxin, a potent blocker of the Gi, blocks the ability of PYY3-36 to 
enhance renovascular responses to Ang II.  This finding confirms that the effects 
of PYY3-36 are mediated by the Gi pathway as well. 
 
 The findings of chapter three have important implications regarding the pathophysiology 
of genetic hypertension.  Renal sympathetic nerves release two major neurotransmitters, 
norepinephrine and NPY [21].   Norepinephrine causes direct vasoconstriction by α1-
adrenoceptors that reside within the neuroeffector junction [21].  Importantly, NPY can bind to 
 and activate Y1 and Y2 receptors [25,34].  Our findings indicate, therefore, that an important 
contributing cause to genetic hypertension could be co-release of NPY from renal sympathetic 
nerves with subsequent activation of postjunctional Y1 receptors, and perhaps to a much lesser 
extent Y2 receptors, leading to significant potentiation of the renal vasoconstrictor responses to 
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FIGURE 7.3 
 This is a diagram of our secondary results.  Ang II signaling is more active in the SHR.  
Activation of the Y2- Gi pathway via PYY3-36, a selective Y2 agonist,  potentiates Ang II 
signaling in the SHR but not WKY.  BIIE0246 and PT block the PYY3-36 induced potentiation of 
Ang II signaling in SHR. 
BIIE0246 
PT 
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Ang II.  The fact that acute blockade of Y1 receptors does not lower arterial blood pressure in 
SHR [63] does not disprove this hypothesis.  Acute blockade of the Y1 receptor would result in 
an increase in Y2 receptor activation which also has the ability to potentiate Ang II responses in 
SHR as demonstrated in chapter 3.  Chronic treatment, on the other hand, would result in a 
decrease in NPY release by the negative feedback of the prejunctional Y2 receptor.   Thusly, we 
suspect that the chronic administration of the Y1 receptor antagonist would lead to a lower 
arterial blood pressure in SHR by lowering direct NPY vasoconstriction and causing a leftward 
shift in the renal-pressure natriuresis relationship. 
 It has long been known that chronic treatment of SHR with α1-adrenoceptor blockers 
does not alter the course of hypertension in SHR [64].  Because α1-adrenoceptors are primarily 
responsible for sympathetically-mediated direct vasoconstriction in the kidney, these data would 
appear to rule out the involvement of renal sympathetic nerves in the pathophysiology of genetic 
hypertension.  However, chronic denervation of the SHR kidney both delays the development of 
hypertension and attenuates the maximum increase in blood pressure[8-11] in SHR, findings 
consistent with a role for the renal sympathetic nerves in hypertension, yet inconsistent with the 
results of studies with α1-adrenoceptor blockers.  Moreover, the profound effects of renal 
denervation on the natural history of hypertension in SHR are seemingly at odds with the 
important role of the renin-angiotensin system in genetic hypertension.  Our hypothesis would 
unify these facts by postulating that the problem is not over-activation of α1-adrenoceptors or 
over-activation of the renin-angiotensin system, but rather normal levels of stimulation of Y1 
receptors, and perhaps to a lesser extent Y2 receptors, leading to potentiation of the renal 
vasoconstrictor responses to normal levels of Ang II in SHR, but not WKY, kidneys.  These 
ideas were further explored in chapter four and chapter five and discussed more later in this 
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chapter.  From chapter three, it would appear that Y1 receptors would take the leading role in this 
scenario because the efficacy of Y2 receptors with regard to potentiating Ang II-induced renal 
vasoconstriction seems quite low.   
   
 Why does Y1 and Y2 receptor activation potentiate Ang II-induced renal vasoconstriction 
in SHR, but not WKY, kidneys?  One possibility is that Y1 and Y2 receptor levels are elevated in 
the kidneys of SHR.  However, we are unable to detect an increase in either Y1 or Y2 receptor 
mRNA or protein in either whole kidneys or preglomerular microvessels freshly isolated from 
whole kidneys.  Thus, it appears that the mechanism for the enhanced Y1 and Y2 receptor 
activation does not involve over-expression of receptors, but rather enhanced coincidence 
signaling between the Ang II and Y1 and Y2 receptor signal transduction pathways in SHR 
kidneys.  In this regard, previous work from our laboratory indicates that the Gi pathway 
mediates potentiation of Ang II-induced renal vasoconstriction by α2-adrenoceptors in SHR[12].  
The present study shows that pertussis toxin, which ADP ribosylates and inactivates Gi, blocks 
the potentiation of Ang II-induced renal vasoconstriction by Y1 and Y2 receptors in the SHR.  
Thus, like α2-adrenoceptors, Y1 and Y2 receptors appear to enhance renovascular responses to 
Ang II in the SHR by activating the Gi pathway.  Several other studies implicate over-expression 
of Gi proteins in some tissues in SHR[65-67].  However, our studies suggest normal levels of Gi 
proteins in SHR preglomerular microvessels[70], and indicate a role for the Gi 
protein/phospholipase C(PLC)/protein kinase C/c-src/phosphatidylinositol 3-kinase pathway in 
the interaction between Ang II and the Gi signal transduction pathway in SHR[71].  Although we 
do not know why coincidence signaling between the Ang II signal transduction pathway and the 
Gi signal transduction pathway is enhanced in SHR kidneys, it appears to be due to a 
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downstream event in the aforementioned signal transduction pathway.  Our leading theory is the 
action each signaling pathway has on PLC.  In this respect, Ang II binds the AT1R which is 
coupled to the Gq pathway.  Once the Gq pathway is activated, the heterotrimeric G-protein 
releases its α subunit (αq), and αq then binds and activates PLC; however, PLC augments the 
intrinsic GTPase activity of αq (that is to say that PLC is a GTPase-activating protein (GAP) and 
therefore “GAPs” αq). Therefore PLC increases the rate of GTP hydrolyses by αq resulting in the 
release of the subunit and deactivation of PLC.  Activation of the Gi pathway results in the 
release of its βγ subunit (βγ).  βγ binds PLC and inhibits PLC’s GAP activity so it has much less 
ability to inactivate αq.  Therefore, if PLC is activated by αq and βγ binds PLC, PLC can no 
longer release αq resulting in increased signaling/response.[72] The demonstrated mechanism 
mentioned here would suggest that WKY and SHR should have increased responses when both 
these signaling pathways are activated, yet our results reveal that only SHR demonstrates an 
increased response.  There has been the suggestion of a scaffolding protein that protects PLC 
from βγ.  We are currently investigating this protein as the potential target where SHR and WKY 
differ resulting in only SHR having an increased response.  However, additional studies are 
required to identify more precisely the involved mechanisms. 
 
 To the best of our knowledge, chapter three represents the first investigation of the 
interaction between Ang II and Y1 and Y2 receptors on renovascular resistance in either 
normotensive or hypertensive animals.  However, Mohy El-Din and Malik have examined the 
effects of high concentrations of NPY (17 nmoles/L), a potent endogenous agonist that activates 
non-selectively Y1, Y2 and Y5 receptors[25,34], on Ang II-induced renal vasoconstriction in 
isolated, perfused kidneys obtained from normotensive Sprague-Dawley rats [73].  Their studies 
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showed that NPY at the concentration employed transiently increased basal renal perfusion 
pressure by approximately 58% and potentiated the changes in renal perfusion pressure induced 
by bolus injections of Ang II by approximately 32%.  Thus, the work by Mohy El-Din and Malik 
indicates that high concentrations of a “broad-spectrum” PP-fold peptide receptor agonist 
enhance Ang II-induced renal vasoconstriction in normotensive animals.  In the present study, 
we did not examine the interaction between Ang II and concentrations of LPNPY greater than 10 
nmoles/L because at higher concentrations LPNPY caused a marked and sustained increase in 
basal renal perfusion pressure that would have confounded interpretation of the interaction 
between LPNPY and Ang II. 
 
 The focus of chapter three was on the interaction between Y1 and Y2 receptors and Ang 
II.  It is well known that in many vascular preparations[74,75], including the isolated, perfused 
rat kidney[76], neuropeptide Y enhances norepinephrine-induced vasoconstriction.  Whether this 
interaction is greater in SHR, compared with WKY, kidneys is an important and open question 
that should be addressed in future studies.  Along these lines, a very recent study by Vonend at 
all[77] indicates that Y1-receptor activation enhances purinergic, nonadrenergic renal 
vasoconstriction in isolated, perfused kidneys from young and adult WKY and young stroke-
prone SHR, but not in kidneys from adult stroke-prone SHR.  Thus, the greater enhancement of 
vasoconstrictor responses in SHR, compared with WKY, kidneys by Y1 receptors may occur 
with only some (for example Ang II) vasoconstrictors.  Indeed, our previous studies demonstrate 
that activating the Gi pathway with the α2-adrenoceptor agonist UK14,304 potentiates 
renovascular responses to Ang II, but not to the α1-adrenoceptor agonist methoxamine in the 
SHR kidney[59].   
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 7.2   Naturally Occurring PP-Fold Receptor Agonists, Especially Y1 Agonists, Enhance 
Ang II Induced Renal Vasoconstriction And Synergize With α2-Adrenoreceptor Agonists 
 
Y1 receptors augment renovascular responses to Ang II in SHR kidneys. The renal 
microcirculation should be exposed to NPY (released from renal sympathetic nerves) and PYY 
(secreted by intestinal cells into the systemic circulation).  NPY and PYY are Y1-receptor 
agonists.  These facts provide a compelling rationale for the hypothesis that the naturally-
occurring Y1-receptor agonists NPY and PYY potentially could play a role with regard to 
enhancing Ang II-induced renal vasoconstriction in genetic hypertension.  Accordingly, a major 
goal of chapter four was to determine and compare the effects of NPY and PYY on renovascular 
responses to Ang II in isolated, perfused kidneys obtained from SHR.  Importantly, this chapter  
confirmed that both NPY and PYY have the ability to potentiate renovascular responses to Ang 
II in SHR kidneys.  Moreover, this potentiation appears to be mediated mostly by the Y1 receptor 
because the effects of both NPY and PYY are abrogated by the highly selective Y1-receptor 
antagonist BIBP3226. 
 
The present study illustrates the capacity of NPY and PYY to potentiate renovascular 
responses in genetic hypertension.  In this regard, as represented in figure 7.4, our results 
demonstrate: 
1) The threshold concentration of naturally-occurring PP-fold Y1-receptor 
agonists for enhancing the responses to Ang II in SHR is equal to or less than 
1 nmole/L.   
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2) The potential of Y2-receptor agonists to alter responses to Ang II is 
minuscule. 
 
In respect to the primary finding in this chapter, as discussed in the chapter four summary, 
this concentration (1 nmole/L) is an upper limit for the in vivo threshold concentration because 
small peptides commonly bind tightly to various surfaces.  Because sympathetic nerve terminals 
release NPY directly onto vascular smooth muscle, it seems likely that such concentrations (1 
nmole/L) should be achieved locally with elevated renal sympathetic tone; however, direct 
evidence for this concept is not available.  With regard to PYY, in rats systemic levels of 
immunoreactive PYY can reach 0.1 nmoles/L to 0.25 nmoles/L.[61]  Although this concentration 
is only 10 to 20% of the nominal in vitro threshold concentration required for potentiation after a 
few minutes of exposure, it is conceivable that over longer periods of time, these lower 
concentrations could accumulate causing a potentiated response to Ang II in kidneys from 
genetically-susceptible animals and human beings. 
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 FIGURE 7.4 
 This is a diagram of the results that compare the naturally occurring PP-fold peptides’ 
ability to augment Ang II signaling in SHR.  PYY demonstrates the most ability to augment Ang 
II-induced renal vasoconstriction while PYY3-36 seems to slightly affect Ang II signaling.  This 
data suggests that the Y1-Gi pathway is more responsible for effecting change in renal responses 
to Ang II as compared to the Y2-Gi pathway. 
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Related to the discussion of whether endogenous levels of NPY and PYY are high enough 
to enhance renal vascular responses to Ang II is the concept that renal vascular smooth muscle 
cells are bathed by circulating catecholamines and catecholamines released from renal 
sympathetic nerves and are simultaneously under the influence of circulating PP-fold peptides 
and PP-fold peptides released from renal sympathetic nerves.  Catecholamines can activate α2-
adrenoceptors, and like Y1 receptors, α2-adrenoceptors are also coupled to Gi proteins.  Because 
α2-adrenoceptors and Y1 receptors couple to Gi proteins, it is possible that co-activation of α2-
adrenoceptors synergizes with PP-fold peptides with regard to enhancing renovascular responses 
to Ang II in kidneys from genetically hypertensive rats.  Indeed chapter four shows, as also 
demonstrated in figure 7.5, that: 
 
3) Low-level stimulation of α2-adrenoceptors synergizes with NPY and PYY with 
regard to potentiating renovascular responses to Ang II in isolated, perfused kidneys from 
SHR.   
 
This study also demonstrates that:  
 
4) Selective Y1-receptor activation with LPNPY and selective α2-adrenoceptor 
simulation with UK14,304 interact to determine the renovascular response to Ang II in kidneys 
from genetically hypertensive animals and that this interaction occurs in vivo and is more robust 
in SHR compared with WKY rats. 
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FIGURE 7.5 
 This is a diagram of the results that reveal a synergy between the naturally occurring PP-
fold peptides and catecholamines, such as NE. Low level activation of the Y1-Gi pathway can 
combine with low level activation of the α2-adrenoreceptor-Gi pathway to potentiate Ang II 
induced renal vasoconstriction in SHR. 
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The findings discussed above suggest that whether endogenous levels of NPY and/or PYY 
are high enough to enhance renovascular responses to Ang II may depend critically on the 
prevailing levels of sympathoadrenal tone.  A broader interpretation of our findings is that any 
Gi-activating factor has the potential to synergize with any other Gi-activating factors with 
regard to augmenting renovascular responses to Ang II.  In this respect, activation of multiple Gi-
activating factors would lead to increases in free αi subunits.  These subunits would then have 
the ability to bind to PLC, trapping bound αq subunits from being released, and increase the Ang 
II-induced activation of PLC which would lead to increased renal vascular responses. If this is 
the case, whether NPY and/or PYY enhance renovascular responses to Ang II may depend on 
the prevailing levels of all three factors (NPY, PYY and catecholamines) as well as the 
prevailing levels of other Gi activators such as adenosine via the A1 receptor [78].  Our 
fundamental hypothesis, therefore, is that the net effect of Ang II on renovascular resistance in 
kidneys from genetically-susceptible subjects will depend on the total mix of Gi activators.  We 
hypothesize that NPY, PYY and catecholamines represent three important players in this regard, 
but doubt whether this is an exhaustive list and other endogenous Gi activators most likely 
participate and will be discovered.   
 
Inhibitors of dipeptidyl peptidase IV are being developed for treatment of type 2 diabetes 
[51-56,79], and would be expected to prevent the proteolytic cleavage of PYY to PYY3-36.  
Another implication of this study is that in some patients, inhibitors of dipeptidyl peptidase IV 
could adversely affect renal function and arterial blood pressure by raising PYY levels.  Indeed, 
in further studies we have confirmed that administration of a dipeptidyl peptidase IV inhibitor 
acutely increases arterial blood pressure in SHR (see chapter 6). 
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 7.3 Endogenously Released PP-Fold Receptor Agonists, Via Nerve Stimulation, Enhance 
Ang II-Induced Renal Vasoconstriction In SHR   
  
 Numerous studies show that the renin-angiotensin system is critical for the development 
and maintenance of high blood pressure in SHR, and transplantation studies demonstrate that the 
SHR kidney is essential to the pathophysiology of hypertension in the SHR.  
Other investigations demonstrate that the renal sympathetic nervous system contributes to the 
pathophysiology of hypertension in SHR as well.  However, a coherent hypothesis that explains 
the co-involvement of the renin-angiotensin system, the sympathetic nervous system and the 
kidneys in SHR hypertension is lacking.   
 
 The results of chapter five demonstrate that renal sympathetic nerves enhance 
renovascular responses to Ang II in SHR, but not WKY, kidneys, and this finding provides a 
critical link that connects the three pathophysiological systems (i.e., renal system, renin-
angiotensin system and renal sympathetic nervous system).  This unifying hypothesis proposes 
that hypertension in SHR is due in part to a genetic abnormality in the renal microcirculation that 
allows the renal sympathetic nerves to potentiate Ang II-induced renal vasoconstriction, thus 
causing long-term changes in renal function. 
 
 In chapter five, our results, also represented in figure 7.6, confirm: 
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FIGURE 7.6 
 This is a diagram of the results that demonstrate renal nerve stimulation as a potentiator 
of renal responses in SHR.  Stimulation of the sympathetic nerves would lead to the release of 
NPY and NE that synergize to have a potentiating effect on renal response induced by Ang II.  
Rauwolscine, an α2-adrenoreceptor blocker, slightly blocks RNS potentiation of renal responses.  
BIBP3226 and PT completely abrogate RNS potentiation of renal responses suggesting that the 
Y1-Gi pathway plays the predominate role in RNS potentiation. 
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1) A physiological level (5 Hz) of stimulation of the renal periarterial nerves, results 
in a near doubling of the renovascular response to a physiological level (100 
pmoles/L) of Ang II in kidneys from SHR.   
2) In kidneys from WKY rats, periarterial nerve stimulation does not significantly 
alter vasoconstrictor responses to Ang II.   
3) BIBP3226 and pertussis toxin completely abrogate renovascular responses to 
renal nerve stimulation while rauwolscine has little effect on increased 
renovascular responses to nerve stimulation. 
 Thus, we conclude that in kidneys from genetically hypertensive rats, but not kidneys 
from normotensive rats, physiological levels of renal sympathetic nerve stimulation enhance 
renovascular responses to physiological levels of Ang II. 
 
The results of this chapter further show that blockade of Gi with pertussis toxin abolishes 
the ability of renal sympathetic nerve stimulation to enhance renovascular responses to Ang II in 
SHR kidneys.  This finding indicates that renal sympathetic nerve stimulation augments 
renovascular responses to Ang II in SHR kidneys via a Gi signal transduction pathway. 
Importantly, previous research as well as research from earlier chapters three and four, indicate 
that the Gi signal transduction mechanism mediates in part the enhanced renovascular response 
to Ang II in SHR.  For example, pertussis toxin, an inhibitor of Gi, abolishes the increased 
renovascular response to Ang II in SHR in vivo[18].   The fact that pertussis toxin blocks both 
the enhanced renovascular responses to Ang II in SHR kidneys in vivo and the ability of renal 
sympathetic nerves to augment Ang II-induced renal vasoconstriction in vitro is critical support 
for the hypothesis that enhanced renovascular responses to Ang II in SHR are mediated in part 
via activation of renal sympathetic nerves.  Published studies by us[19] and others[69] 
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demonstrate that pertussis toxin is antihypertensive in SHR, and the results of the present study 
are consistent with that conclusion.  The antihypertensive action of pertussis toxin in SHR is also 
consistent with our aforementioned unifying hypothesis regarding the pathophysiology of 
hypertension in SHR. 
 
 Our previous studies show that activation of the Gi pathway by agonists of α2-
adrenoceptors or Y1 receptors or by co-activation of both α2-adrenoceptors or Y1 receptors 
potentiates renovascular response to Ang II in SHR kidneys.  Because renal sympathetic nerves 
release both norepinephrine and NPY, which activate α2-adrenoceptors and Y1 receptors, 
respectively, we anticipated that the ability of renal sympathetic nerve stimulation to augment 
renovascular responses to Ang II would be attenuated somewhat by both rauwolscine (an α2-
adrenoceptor antagonist) and BIBP 3226 (a Y1 receptor antagonist), but not completely by either.  
In contrast to our expectations, rauwolscine did not significantly affect the ability of renal 
sympathetic nerve stimulation to augment renovascular responses to Ang II, whereas BIBP 3226 
completely abrogated stimulation-induced enhancement of Ang II responses.  A conflicting issue 
is that administration of rauwolscine would lead to upregulation of NPY and NE release via 
blockade of presynaptic α2-adrenoceptors;  however, complete abrogation of RNS increases in 
Ang II activity via blockade of the Y1 receptor suggests that NPY plays a more predominate role 
in these RNS responses.  In correlation, norepinephrine mainly undergoes prejunctional and 
postjunctional uptake and therefore would have limited access to α2-adrenoceptors, which are 
known to be primarily extrajunctional[80], therefore, NE alone may have difficulty activating its 
receptor. On the other hand, NPY does not undergo uptake and, even in the absence of NE, 
would be available to diffuse to both junctional and extrajunctional Y1 receptors.  If this 
hypothesis is correct, this leaves open the possibility that circulating catecholamines, for 
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example from the adrenal gland, as well as circulating endogenous agonists of Y1 receptors, for 
example PYY released from intestines, may also enhance renovascular responses to Ang II in 
SHR under the appropriate conditions.   
 
 7.4 PYY’s  Conversion To PYY3-36 Via Dipeptidyl Peptidase IV May Attentuate 
The Hypertensive Effect Of PYY 
Chapters three, four, and five of this work have began to demonstrate a link between the 
kidney, renin-angiotensin system, and the sympathetic nervous system in the increased blood 
pressure of the SHR.  In this regard, hormones released during sympathetic nerve stimulation, 
namely NPY and norepinephrine, interact in the kidney with the renin-angiotensin system via a 
Gi-dependent mechanism to cause an acute increase in Ang II-induced renovasoconstriction in 
the genetically susceptible SHR. Yet, NPY is a member in a group of peptides labeled PP-fold 
peptides.  This group also includes PYY which is a gastrointestinally-released Y1 agonist.  
Chapter four further demonstrates that PYY has similar if not more ability than NPY to augment 
Ang II induced renal vasoconstriction, and that in the presence of an α2-adrenoreceptor agonist, 
these two Gi coupled agonist significantly potentiate Ang II induced renal vasoconstriction in 
SHR.  However, as mentioned in the background, PYY is most often found in the serum in its 
truncated form (PYY3-36) especially following the release of the PP-fold peptides due to a high 
fat meal.[42-46]  The proteolytic cleavage of PYY by DPPIV is the major focus of chapter six. 
 
The results from chapter six reveal an important role in protection from acute increases in 
blood pressure by the cleavage of PYY to PYY3-36 via DPPIV.  In this regard chapter six 
demonstrates: 
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1) P32/98, a commercially available DPPIV inhibitor, given intravenously 
causes an acute increase in mean arterial blood pressure in SHR. 
2) P32/98 has no effect on blood pressure in WKY, normotensive animals. 
3) BIBP3226, a Y1 antagonist, completely abrogates increases in blood pressure 
induced by P32/98 in SHR. 
Thus, we conclude, that the conversion of PYY to PYY3-36 via DPPIV plays a protective 
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FIGURE 7.7 
 This is a diagram of the results that show the role of dipeptidyl peptidase IV in SHR.  
Normally, DPPIV would result in the body having more PYY3-36 than PYY which would have 
little to no effect on renal responses, and thus blood pressure.  The use of DPPIV inhibitor 
P32/98 leads to increases in renal responses, and thus blood pressure, that can be blocked with 
BIBP3226.  This result suggests that P32/98 increased Y1-Gi pathway signaling. 
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role in the genetically suspectible SHR, but no role in the WKY normotensive animal.  We 
further conclude that the primary signaling pathway by which blockade of PYY to PYY3-36 
elicits increases in blood pressure is through the Y1 receptor pathway.   
 
The results of previous research, chapters three and four, suggested the possibility that 
DPPIV may play a role in the renal response to Ang II in SHR.  In this regard, our earlier results 
demonstrated that PYY had a significant effect on Ang II induced renovasoconstriction via the 
Y1-Gi pathway in SHR, but not WKY kidneys.  On the other hand, PYY3-36 which is known to 
only act via the Y2 receptor pathway elicited little to no effect on Ang II induced 
renovasoconstriction in SHR or WKY, and had no ability to synergize with UK14,304 to elicit 
an augmentation.  To the best of our knowledge, this is the first study where the role of DPPIV 
inhibition has demonstrated an effect on blood pressure.  Altered serum DPPIV activity have 
been observed in a number of diseases including different malignant processes, liver diseases 
and osteoporosis, and DPPIV levels have been shown to be influenced by psychiatric disorders.  
Yet, there has been no correlation between DPPIV levels and blood pressure.[56]  One possible 
explanation is that the parameters surrounding DPPIV levels have only been observed in normal 
patients.  Our results reveal that in normotensive WKY animals blockade of DPPIV had no 
effect on blood pressure which would confirm no correlation between DPPIV and blood 
pressure.  However, in animals that are genetically prone to hypertension, for example SHR , the 
level and ability of DPPIV to act may be essential.  Concurrent acute increases in blood pressure 
could eventually have a detrimental effect in the long term. 
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 Importantly, as discussed in the introduction, DPPIV inhibitors have become an 
important pharmacological controller of blood glucose level.[51-56]  Inhibitors of DPPIV result 
in the upregulation of GLP-1 which leads to increased blood glucose handling.  While this could 
be beneficial in the pathophysiology of type II diabetes, the findings of the current study would 
suggest that some individuals may not handle this therapy well.  In a subset of patients that have 
similar genetic abnormalities as the SHR, this type of therapy would lead to at least acute 
increases in blood pressure that over time could become a chronic problem. 
  
7.5 Medical Perspectives 
The renal sympathetic nervous system and renin-angiotensin system interact at multiple 
levels to regulate renal vascular tone, and hence long-term levels of arterial blood pressure.  
Augmentation of any of these interactions could participate in the pathophysiology of high blood 
pressure.  The present experiments demonstrate that in SHR, but not WKY, kidneys, renal 
sympathetic nerve stimulation augments the ability of Ang II to constrict the renal circulation.  
The mechanism of this augmentation mainly involves Y1 receptors signaling via the Gi 
transduction pathway.  Previous studies by many investigators implicate the renal system, the 
renin-angiotensin system and the sympathetic nervous system in the pathophysiology of genetic 
hypertension.  Furthermore, the present study demonstrates that the gastrointestinal system may 
also play a role in the pathophysiology of genetic hypertension.  Similar to renal nerve 
stimulation, the augmentation observed via gastrointestinal sources mainly involves Y1 receptors 
signaling via the Gi transduction pathway.  The implications of the experiments reported here 
provide a possible explanation for the co-involvement of these systems in genetic hypertension.   
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